

# Mapping neurotransmitter systems to the structural and functional organization of the human neocortex

Received: 1 November 2021

Accepted: 20 September 2022

Published online: 27 October 2022

 Check for updates


Justine Y. Hansen<sup>1</sup>, Golia Shafiei<sup>1</sup>, Ross D. Markello<sup>1</sup>, Kelly Smart<sup>2,3</sup>, Sylvia M. L. Cox<sup>4</sup>, Martin Nørgaard<sup>5,6</sup>, Vincent Beliveau<sup>6,7</sup>, Yanjun Wu<sup>2,3</sup>, Jean-Dominique Gallezot<sup>2,3</sup>, Étienne Aumont<sup>8</sup>, Stijn Servaes<sup>9</sup>, Stephanie G. Scala<sup>4</sup>, Jonathan M. DuBois<sup>10</sup>, Gabriel Wainstein<sup>11</sup>, Gleb Bezgin<sup>1,9</sup>, Thomas Funck<sup>12</sup>, Taylor W. Schmitz<sup>13</sup>, R. Nathan Spreng<sup>1</sup>, Marian Galovic<sup>14,15,16</sup>, Matthias J. Koepp<sup>15,16</sup>, John S. Duncan<sup>15,16</sup>, Jonathan P. Coles<sup>17</sup>, Tim D. Fryer<sup>18</sup>, Franklin I. Aigbirhio<sup>18</sup>, Colm J. McGinnity<sup>19</sup>, Alexander Hammers<sup>19</sup>, Jean-Paul Soucy<sup>1</sup>, Sylvain Baillet<sup>1</sup>, Synthia Guimond<sup>20,21</sup>, Jarmo Hietala<sup>22</sup>, Marc-André Bedard<sup>1,8</sup>, Marco Leyton<sup>1,4</sup>, Eliane Kobayashi<sup>1</sup>, Pedro Rosa-Neto<sup>1,9</sup>, Melanie Ganz<sup>6</sup>, Gitte M. Knudsen<sup>6,23</sup>, Nicola Palomero-Gallagher<sup>12,24</sup>, James M. Shine<sup>11</sup>, Richard E. Carson<sup>2,3</sup>, Lauri Tuominen<sup>20</sup>, Alain Dagher<sup>1</sup> and Bratislav Misic<sup>1</sup> ✉

Neurotransmitter receptors support the propagation of signals in the human brain. How receptor systems are situated within macro-scale neuroanatomy and how they shape emergent function remain poorly understood, and there exists no comprehensive atlas of receptors. Here we collate positron emission tomography data from more than 1,200 healthy individuals to construct a whole-brain three-dimensional normative atlas of 19 receptors and transporters across nine different neurotransmitter systems. We found that receptor profiles align with structural connectivity and mediate function, including neurophysiological oscillatory dynamics and resting-state hemodynamic functional connectivity. Using the Neurosynth cognitive atlas, we uncovered a topographic gradient of overlapping receptor distributions that separates extrinsic and intrinsic psychological processes. Finally, we found both expected and novel associations between receptor distributions and cortical abnormality patterns across 13 disorders. We replicated all findings in an independently collected autoradiography dataset. This work demonstrates how chemoarchitecture shapes brain structure and function, providing a new direction for studying multi-scale brain organization.

Neurotransmitter receptors are heterogeneously distributed across the neocortex and respond to the binding of a neurotransmitter. By modulating the excitability and firing rate of the cell, neurotransmitter receptors effectively mediate the transfer and propagation of

electrical impulses. As such, neurotransmitter receptors drive synaptic plasticity, modify neural states and ultimately shape network-wide communication<sup>1</sup>. These receptors are diverse in their structure and function: receptors may be ionotropic or metabotropic, may be

A full list of affiliations appears at the end of the paper. ✉ e-mail: [bratislav.misic@mcgill.ca](mailto:bratislav.misic@mcgill.ca)



**Fig. 1 | PET images of neurotransmitter receptors and transporters.** PET tracer images were collated and averaged to produce mean receptor distribution maps of 19 different neurotransmitter receptors and transporters across nine different neurotransmitter systems and a combined total of more than 1,200 healthy participants.

composed of multiple subunits, may exert facilitatory or inhibitory influence on the circuit and are coupled to different downstream biochemical pathways.

How spatial distributions of different neurotransmitter receptors relate to brain structure and shape brain function at the system level remains unknown. Recent technological advances allow for high-resolution reconstructions of the brain's wiring patterns. These wiring patterns display non-trivial architectural features, including specialized network modules that support the segregation of information<sup>2</sup> as well as densely interconnected hub regions that support the integration of information<sup>3</sup>. The spatial arrangement of neurotransmitter receptors on this network presumably guides the flow of information and the emergence of cognitive function. Therefore, understanding the link between structure and function is inherently incomplete without a comprehensive map of the chemoarchitecture of the brain<sup>4,5</sup>.

A primary obstacle to studying the relative density distributions of receptors across multiple neurotransmitter systems is the lack of comprehensive openly accessible datasets. An important exception is the autoradiography dataset of 15 neurotransmitter receptors and receptor-binding sites, collected in three postmortem brains<sup>4,6</sup>. However, these autoradiographs are available in only 44 cytoarchitecturally defined cortical areas. Alternatively, positron emission tomography (PET) can estimate in vivo receptor concentrations across the whole brain. Despite the relative ease of mapping receptor densities using PET, there are, nonetheless, difficulties in constructing a comprehensive PET dataset of neurotransmitter receptors. Due to the radioactivity of the injected PET tracer, mapping multiple different receptors in the same individual is not considered a safe practice. Combined with the fact that PET image acquisition is relatively expensive, cohorts of control subjects are small and typically include only one or two tracers. Therefore, constructing a comprehensive atlas of neurotransmitter receptor densities across the brain requires extensive data-sharing efforts from multiple research groups<sup>7–11</sup>.

Here we curate and share an atlas of PET-derived whole-brain neurotransmitter receptor maps from 19 unique neurotransmitter receptors, receptor-binding sites and transporters, across nine different neurotransmitter systems and more than 1,200 healthy individuals,

available at [https://github.com/netneurolab/hansen\\_receptors](https://github.com/netneurolab/hansen_receptors). We use multiple imaging modalities to comprehensively situate cortical neurotransmitter receptor densities within micro-scale and macro-scale neural architectures. Using diffusion-weighted magnetic resonance imaging (MRI) and functional MRI, we show that neurotransmitter receptor densities follow the organizational principles of the brain's structural and functional connectomes. Moreover, we found that neurotransmitter receptor densities shape magnetoencephalography (MEG)-derived oscillatory neural dynamics. To determine how neurotransmitter receptor distributions affect cognition and disease, we mapped receptor densities to meta-analytic (Neurosynth-derived) functional activations, where we uncovered a spatially co-varying axis of neuromodulators and mood-related processes. Next, we linked receptor distributions to ENIGMA-derived patterns of cortical atrophy across 13 neurological, psychiatric and neurodevelopmental disorders, uncovering specific receptor–disorder links. We validated our findings and extended the scope of the investigation to additional receptors using an independently collected autoradiography neurotransmitter receptor dataset<sup>6</sup>. Altogether, we demonstrate that, across spatial and temporal scales, chemoarchitecture consistently plays a key role in brain function.

## Results

A comprehensive cortical profile of neurotransmitter receptor densities was constructed by collating PET images from a total of 19 different neurotransmitter receptors, transporters and receptor-binding sites across nine different neurotransmitter systems, including dopamine, norepinephrine, serotonin, acetylcholine, glutamate, GABA, histamine, cannabinoid and opioid (Fig. 1). All PET images were acquired in healthy participants (see Table 1 for a complete list of receptors and transporters, corresponding PET tracers, ages and number of participants). A group-average tracer map was constructed across participants within each study. To mitigate variation in image acquisition and pre-processing, and to ease biological interpretability, all PET tracer maps were parcellated into the same 100 cortical regions and z-scored<sup>12</sup>. Note that, although the data include both cortical and subcortical data, we restricted our analyses to the cortex. In total, we present tracer maps

for 19 unique neurotransmitter receptors and transporters from a combined total of 1,238 healthy participants, resulting in a  $100 \times 19$  matrix of relative neurotransmitter receptor/transporter densities. Finally, we repeated all analyses in an independently collected autoradiography dataset of 15 neurotransmitter receptors (Supplementary Table 1 (ref. <sup>6</sup>)) and across alternative brain parcellations<sup>12</sup>.

### Receptor distributions reflect structural and functional organization

To quantify the potential for two brain regions to be similarly modulated by endogenous or exogenous input, we computed the correlation of receptor/transporter fingerprints between pairs of brain regions (Fig. 2a). Hereafter, we refer to this quantity as ‘receptor similarity’, analogous to other commonly used measures of inter-regional attribute similarity, including anatomical covariance<sup>13</sup>, morphometric similarity<sup>14</sup>, gene coexpression<sup>15</sup>, temporal profile similarity<sup>16</sup> and microstructural similarity<sup>17</sup>. Receptor similarity is approximately normally distributed (Fig. 2b) and decreases exponentially with Euclidean distance, supporting the notion that proximal neural elements share similar microarchitecture (Fig. 2c; refs. <sup>18,19</sup>). We confirm that no single receptor or transporter exerts undue influence on the receptor similarity matrix (see the ‘Sensitivity and robustness analyses’ section).

Receptor similarity addresses the between-region similarity of receptor fingerprints. To complement this, we calculated the first principal component of receptor density, which represents a regional quantification of receptor similarity (Fig. 2d). This gradient separates insular and cingulate cortex from somatomotor and posterior parietal regions and resembles the macaque principal receptor expression gradient<sup>20</sup>. The first principal component differentiates laminar classes, supporting the notion that receptor expression strongly depends on lamination (Fig. 2e; one-way ANOVA  $F = 15.82$ ,  $P = 1.95 \times 10^{-8}$ ; ref. <sup>21</sup>). Additionally, we found a significant correlation between the receptor gradient and synapse density, consistent with the finding that the macaque receptor gradient increases with the number of dendritic spines (Fig. 2f; Pearson’s  $r(98) = 0.44$ ,  $P_{\text{spin}} = 0.0003$ , confidence interval (CI) = [0.26, 0.58], two-tailed)<sup>20</sup>. For completeness, we stratified receptors by biological mechanisms (excitatory/inhibitory, ionotropic/metabotropic and Gs-/Gi-/Gq-coupled metabotropic pathways) and neurotransmitter protein structure (monoamine/non-monoamine) to provide additional insight about the underlying biological pathways (Fig. 2g).

Using group-consensus structural and resting-state functional connectomes from the Human Connectome Project (HCP), we show that neurotransmitter receptor organization reflects structural and functional connectivity. Specifically, we found that receptor similarity is greater between pairs of brain regions that are structurally connected, suggesting that anatomically connected areas are likely to be co-modulated (Fig. 3a). To ensure that the observed relationship between structural connections and receptor similarity is not due to spatial proximity or network topography, we assessed significance against density-, degree- and edge length-preserving surrogate structural connectivity matrices ( $P = 0.0001$ , 10,000 repetitions<sup>22</sup>). Additionally, we found that receptor similarity is significantly correlated with structural connectivity, after regressing Euclidean distance from both modalities (Pearson’s  $r(1134) = 0.16$ ,  $P = 1.6 \times 10^{-8}$ , CI = [0.11, 0.23], two-sided).

Likewise, receptor similarity is significantly greater between brain regions that are within the same intrinsic networks than between different intrinsic networks, according to the Yeo–Krienen seven-network classification ( $P_{\text{spin}} = 0.001$ , 10,000 repetitions; Fig. 3b (ref. <sup>23</sup>)). This suggests that areas that are in the same cognitive system tend to have similar receptor profiles<sup>4</sup>. Significance was assessed non-parametrically by permuting the intrinsic network affiliations while preserving spatial autocorrelation (‘spin test’; refs. <sup>24,25</sup>). We also found that receptor similarity is significantly correlated with functional connectivity,

after regressing Euclidean distance from both matrices (Pearson’s  $r(4948) = 0.23$ ,  $P = 7.1 \times 10^{-61}$ , CI = [0.20, 0.26], two-sided). In other words, we observed that brain regions with similar receptor and transporter composition show greater functional co-activation. Collectively, these results demonstrate that receptor profiles are systematically aligned with patterns of structural and functional connectivity above and beyond spatial proximity, consistent with the notion that receptor profiles guide inter-regional signaling.

Because neurotransmitter receptor and transporter distributions are organized according to structural and functional architectures, we next asked whether receptor/transporter distributions might augment the coupling between brain structure and function. To quantify structure–function coupling, we relied on the communicability of the weighted structural connectome (see results using alternative methods in Supplementary Fig. 1). Communicability represents a form of decentralized diffusive communication on the structural connectome<sup>26</sup> and has been previously shown to mediate the link between brain structure and function<sup>27</sup>. Structure–function coupling at every brain region is defined as the adjusted  $R^2$  of a simple linear regression model that fits regional communicability to regional functional connectivity. We then included regional receptor similarity as an independent variable, to assess how receptor information changes structure–function coupling. Significance was assessed against a null distribution of adjusted  $R^2$  from a model that adds a rotated regional receptor similarity vector (10,000 repetitions, one-sided, false discovery rate (FDR)-corrected). Next, we cross-validated each regression model using a distance-dependent method that was previously developed in-house (Supplementary Fig. 2; see Methods for details<sup>28</sup>). We found that including receptor profiles as an input variable alongside brain structure significantly improves the prediction of regional functional connectivity in unimodal areas and the paracentral lobule (Fig. 3c).

### Receptor profiles shape oscillatory neural dynamics

Given that neurotransmitter receptors modulate the firing rates of neurons and, therefore, population activity, we sought to relate the cortical patterning of neurotransmitter receptors to neural oscillations. We used MEG power spectra across six canonical frequency bands from the HCP<sup>29,30</sup>. We fit a multiple linear regression model that predicts the cortical power distribution of each frequency band from neurotransmitter receptor and transporter densities. We then cross-validated the model using a distance-dependent method (Supplementary Fig. 3). In addition to the cross-validation, we assessed the significance of each model against a spin-permuted null model (10,000 repetitions) and found that all models except high-gamma are significant after FDR correction ( $P_{\text{spin}} < 0.05$ , one-sided). We found a close fit between receptor densities and MEG-derived power ( $0.78 \leq R_{\text{adj}}^2 \leq 0.94$ ; Fig. 4a), suggesting that overlapping spatial topographies of multiple neurotransmitter systems may ultimately manifest as coherent oscillatory patterns.

To identify independent variables (receptors/transporters) that contribute most to the fit, we applied dominance analysis, a technique that assigns a proportion of the final  $R_{\text{adj}}^2$  to each independent variable to the statistically significant models<sup>31</sup>. Dominance was normalized by the total fit of the model ( $R_{\text{adj}}^2$ ), such that dominance is comparable across models (Fig. 4b). We found that, compared to other receptors, the spatial distribution of MOR (opioid), H<sub>3</sub> (histamine) and  $\alpha_2$  make a large contribution to the fit between receptors and lower-frequency (theta and alpha) as well as low-gamma power bands<sup>32,33</sup>. Interestingly, we found a prominence of ionotropic receptors when we replicated the analysis in the autoradiography dataset (see the ‘Replication using autoradiography’ section and Supplementary Fig. 4). Additionally, when we stratified dominance by receptor classes, we found that inhibitory, non-monoamine and Gi-coupled receptors are more dominant than excitatory, monoamine and Gs-/Gq-coupled receptors, respectively (Supplementary Fig. 5a).



**Table 1 | Neurotransmitter receptors and transporters included in analyses.** BP<sub>ND</sub>, non-displaceable binding potential; V<sub>T</sub>, tracer distribution volume; B<sub>max</sub>, density (pmol ml<sup>-1</sup>) converted from binding potential (5-HT) or distributional volume (GABA) using autoradiography-derived densities; SUVR, standard uptake value ratio. Values in parentheses (under *n*) indicate the number of females. Neurotransmitter receptor maps without citations refer to previously unpublished data. In those cases, contact information for the study principal investigator (PI) is provided in Supplementary Table 3. Supplementary Table 3 also includes more extensive methodological details, such as PET camera, number of males and females, modeling method, reference region, scan length and modeling notes. Asterisks indicate transporters

Receptor/transporter	Neurotransmitter	Tracer	Measure	<i>n</i>	Age	References
D <sub>1</sub>	Dopamine	[ <sup>11</sup> C]SCH23390	BP <sub>ND</sub>	13 (7)	33±13	Kaller et al. <sup>58</sup>
D <sub>2</sub>	Dopamine	[ <sup>11</sup> C]FLB-457	BP <sub>ND</sub>	37 (20)	48.4±16.9	Smith et al. <sup>59,60</sup>
D <sub>2</sub>	Dopamine	[ <sup>11</sup> C]FLB-457	BP <sub>ND</sub>	55 (29)	32.5±9.7	Sandiego et al. <sup>59-63</sup>
DAT*	Dopamine	[ <sup>123</sup> I]-FP-CIT	SUVR	174 (65)	61±11	Dukart et al. <sup>64</sup>
NET*	Norepinephrine	[ <sup>11</sup> C]MRB	BP <sub>ND</sub>	77 (27)	33.4±9.2	Ding et al. <sup>65-68</sup>
5-HT <sub>1A</sub>	Serotonin	[ <sup>11</sup> C]WAY-100635	BP <sub>ND</sub>	35 (17)	26.3±5.2	Savli et al. <sup>69</sup>
5-HT <sub>1B</sub>	Serotonin	[ <sup>11</sup> C]P943	BP <sub>ND</sub>	65 (16)	33.7±9.7	Gallezot et al. <sup>70-76</sup>
5-HT <sub>1B</sub>	Serotonin	[ <sup>11</sup> C]P943	BP <sub>ND</sub>	23 (8)	28.7±7.0	Savli et al. <sup>69</sup>
5-HT <sub>2A</sub>	Serotonin	[ <sup>11</sup> C]Cimbi-36	B <sub>max</sub>	29 (14)	22.6±2.7	Beliveau et al. <sup>9</sup>
5-HT <sub>4</sub>	Serotonin	[ <sup>11</sup> C]SB207145	B <sub>max</sub>	59 (18)	25.9±5.3	Beliveau et al. <sup>9</sup>
5-HT <sub>6</sub>	Serotonin	[ <sup>11</sup> C]GSK215083	BP <sub>ND</sub>	30 (0)	36.6±9.0	Radhakrishnan et al. <sup>77,78</sup>
5-HTT*	Serotonin	[ <sup>11</sup> C]DASB	B <sub>max</sub>	100 (71)	25.1±5.8	Beliveau et al. <sup>9</sup>
α <sub>4</sub> β <sub>2</sub>	Acetylcholine	[ <sup>18</sup> F]Flubatine	V <sub>T</sub>	30 (10)	33.5±10.7	Hillmer et al. <sup>79,80</sup>
M <sub>1</sub>	Acetylcholine	[ <sup>11</sup> C]LSN3172176	BP <sub>ND</sub>	24 (11)	40.5±11.7	Naganawa et al. <sup>81</sup>
VACHT*	Acetylcholine	[ <sup>18</sup> F]FEOBV	SUVR	4 (1)	37±10.2	PI: Tuominen, L. & Guimond, S.
VACHT*	Acetylcholine	[ <sup>18</sup> F]FEOBV	SUVR	18 (13)	66.8±6.8	Aghourian et al. <sup>82</sup>
VACHT*	Acetylcholine	[ <sup>18</sup> F]FEOBV	SUVR	5 (1)	68.3±3.1	Bedard et al. <sup>83</sup>
VACHT*	Acetylcholine	[ <sup>18</sup> F]FEOBV	SUVR	3 (3)	66.6±0.94	PI: Schmitz, T. W. & Spreng, R. N.
NMDA	Glutamate	[ <sup>18</sup> F]GE-179	V <sub>T</sub>	29 (8)	40.9±12.7	Galovic et al. <sup>84-86</sup>
mGluR <sub>5</sub>	Glutamate	[ <sup>11</sup> C]ABP688	BP <sub>ND</sub>	73 (48)	19.9±3.04	Smart et al. <sup>52</sup>
mGluR <sub>5</sub>	Glutamate	[ <sup>11</sup> C]ABP688	BP <sub>ND</sub>	22 (10)	67.9±9.6	PI: Rosa-Neto, P. & Kobayashi, E.
mGluR <sub>5</sub>	Glutamate	[ <sup>11</sup> C]ABP688	BP <sub>ND</sub>	28 (13)	33.1±11.2	DuBois et al. <sup>87</sup>
GABA <sub>A/BZ</sub>	GABA	[ <sup>11</sup> C]Flumazenil	B <sub>max</sub>	16 (9)	26.6±8	Nørgaard et al. <sup>8</sup>
H <sub>3</sub>	Histamine	[ <sup>11</sup> C]GSK189254	V <sub>T</sub>	8 (1)	31.7±9.0	Gallezot et al. <sup>88</sup>
CB <sub>1</sub>	Cannabinoid	[ <sup>11</sup> C]OMAR	V <sub>T</sub>	77 (28)	30.0±8.9	Normandin et al. <sup>89-92</sup>
MOR	Opioid	[ <sup>11</sup> C]Carfentanil	BP <sub>ND</sub>	204 (72)	32.3±10.8	Kantonen et al. <sup>93</sup>

## Mapping receptors to cognitive function


Previously, we showed that receptor and transporter distributions follow the structural and functional organization of the brain and that receptors are closely linked to neural dynamics. In this and the next subsections, we investigate how the spatial distribution of neurotransmitter receptors and transporters correspond to cognitive processes and disease vulnerability.

We used Neurosynth to derive 123 meta-analytic task activation maps, which represent the probability that specific brain regions are activated during multiple cognitive tasks<sup>34</sup>. We applied partial least squares (PLS) analysis to identify a multivariate mapping between neurotransmitter receptors/transporters and functional activation maps.

PLS analysis extracted a significant latent variable relating receptor/transporter densities to functional activation across the brain ( $P_{\text{spin}} = 0.010$ , one-tailed). The latent variable represents the dominant spatial pattern of receptor distributions (receptor weights) and functional activations (cognitive weights) that together capture 54% of the covariance between the two datasets (Fig. 5a). Projecting the receptor

density (functional activation) matrix back onto the receptor (cognitive) weights reflects how well a brain area exhibits the receptor and cognitive weighted pattern, which we refer to as ‘receptor scores’ and ‘cognitive scores’, respectively (Fig. 5b,c). The receptor and cognitive score patterns reveal a sensory-fugal spatial gradient, separating limbic, paralimbic and insular cortices from visual and somatosensory cortices. We then cross-validated the correlation between receptor and cognitive scores using a distance-dependent method (Fig. 5d, mean out-of-sample Pearson’s  $r(98) = 0.54$ ,  $P_{\text{spin}} = 0.046$ , one-sided). This result demonstrates a link between receptor distributions and cognitive specialization that is perhaps mediated by laminar differentiation and synaptic hierarchies.

To identify the receptors and cognitive processes that contribute most to the spatial pattern in Fig. 5b,c, we correlated each variable with the score pattern (Fig. 5e–f; for all stable term loadings, see Supplementary Fig. 6). This results in a ‘loading’ for each receptor and cognitive process, where positively loaded receptors co-vary with positively loaded cognitive processes in positively scored brain




**Fig. 2 | Constructing a cortical neurotransmitter receptor and transporter atlas.** PET maps for 19 different neurotransmitter receptors and transporters were z-scored and collated into a single neurotransmitter receptor atlas. **a**, For each pair of brain regions, the receptor density profiles are correlated (Pearson's  $r$ ) to construct the receptor similarity matrix (ordered according to the Yeo–Krienen intrinsic networks: frontoparietal, default mode, dorsal attention, limbic, ventral attention, somatomotor and visual<sup>23</sup>). **b**, Receptor similarity is approximately normally distributed. **c**, Receptor similarity decays exponentially with the Euclidean distance between centroid coordinates of brain regions. **d**, The first principal component of receptor density. **e**, The first principal

gradient of receptor density stratified by classes of laminar differentiation reveals a gradient from idiosyncratic regions to paralimbic regions (one-way ANOVA  $F = 15.82$ ,  $P = 1.95 \times 10^{-8}$ ; PLMB, paralimbic; HET, heteromodal; UNI, unimodal; IDT, idiosyncratic). **f**, The principal receptor gradient is significantly correlated with synapse density (measured using the synaptic vesicle glycoprotein 2A-binding [<sup>14</sup>C]-UCBJ PET tracer; Pearson's  $r(98) = 0.44$ ,  $P_{\text{spin}} = 0.0003$ , CI = [0.26, 0.58], two-tailed). **g**, Pearson's correlations between pairs of receptor/transporter distributions are shown stratified by excitatory versus inhibitory, monoamine versus non-monoamine, ionotropic versus metabotropic and Gs-coupled versus Gq-coupled metabotropic receptors.

regions and vice versa for negative loadings. Interestingly, we found that almost all receptors/transporters have positive loading, with metabotropic dopaminergic and serotonergic receptors having the greatest loadings (Fig. 5e and Supplementary Fig. 5b). The cognitive processes with large positive loadings are enriched for emotional and affective processes such as ‘emotion’, ‘fear’ and ‘valence’. This suggests that the combination of serotonergic and dopaminergic receptor distributions co-vary with mood-related functional activation in insular and limbic regions, consistent with the role of serotonin and dopamine neurotransmitter systems in mood processing and mood disorders<sup>35</sup>. On the other hand, we found that only NET has stable negative loading and that it spatially co-varies with functions such as ‘fixation’, ‘planning’ and ‘skill’ in primarily unimodal regions. This is consistent with the notion that norepinephrine systems are involved in integrative functions that require coordination across segregated brain regions<sup>1</sup>. Collectively, these results demonstrate a direct link between cortex-wide molecular receptor distributions and functional specialization.

**Mapping receptors and transporters to disease vulnerability** Neurotransmitter receptors and transporters are implicated in multiple diseases and disorders. Identifying the neurotransmitter receptors/transporters that correspond to specific disorders is important for developing new therapeutic drugs. We, therefore, sought to relate neurotransmitter receptors and transporters to patterns of cortical abnormality across a range of neurological, developmental and psychiatric disorders. We used datasets from the ENIGMA consortium for a total of 13 disorders, including 22q11.2 deletion syndrome, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), idiopathic generalized epilepsy (IGE), right and left temporal lobe epilepsy, depression, obsessive-compulsive disorder (OCD), schizophrenia, bipolar disorder (BD), obesity, schizotypy and Parkinson's disease (PD). We then fit a multiple regression model that predicts each disorder's cortical abnormality pattern from receptor and transporter distributions (Fig. 6). We assessed the significance of each model fit against an FDR-corrected one-sided spatial autocorrelation-preserving null model and evaluated each model using distance-dependent



**Fig. 3 | Receptor distributions reflect structural and functional organization.**

**a**, Top: group consensus weighted structural connectivity matrix. Middle: Receptor similarity is significantly greater between regions that are physically connected, against distance- and edge length-preserving null structural connectivity matrices ( $P = 0.0001$ , two-tailed,  $N_{\text{connected}} = 1,136$  edges,  $N_{\text{not connected}} = 3,814$  edges<sup>22</sup>). Bottom: Receptor similarity is significantly positively correlated with structural connectivity, after distance regression (Pearson's  $r(1134) = 0.16$ ,  $P = 1.6 \times 10^{-8}$ , CI = [0.11, 0.23], two-sided). **b**, Top: group-average functional connectivity matrix. Middle: Receptor similarity is significantly greater within regions in the same functional network ( $P_{\text{spin}} = 0.001$ , two-tailed,  $N_{\text{within}} = 762$  edges,  $N_{\text{between}} = 4,188$  edges). Bottom: Receptor similarity is positively correlated with functional connectivity (Pearson's  $r(4948) = 0.23$ ,  $P = 7.1 \times 10^{-61}$ , CI = [0.20, 0.26], two-sided). **c**, Regional structure–function coupling was

computed as the fit ( $R^2_{\text{adj}}$ ) between communicability of the weighted structural connectome and functional connectivity. Top: Structure–function coupling at each brain region is plotted when receptor similarity is excluded (x-axis) and included (y-axis) in the model. Yellow points indicate brain regions where receptor information significantly augments structure–function coupling ( $P_{\text{spin}} < 0.05$ , FDR-corrected, one-sided). Bottom: the difference in adjusted  $R^2$  when receptor similarity is and is not included in the regression model. Asterisks in **a** and **b** denote significance. Box plots in **a** and **b** represent the 1st, 2nd (median) and 3rd quartiles; whiskers represent the non-outlier endpoints of the distribution; and diamonds represent outliers. Connectomes in **a** and **b** are ordered according to the Yeo–Krienen intrinsic networks (order: frontoparietal, default mode, dorsal attention, limbic, ventral attention, somatomotor and visual)<sup>23</sup>. sc, structural connectivity.


cross-validation (Supplementary Fig. 7). Figure 6a shows how receptor distributions map onto cortical abnormality patterns across multiple disorders. We found that some disorders are more heavily influenced by receptor distribution than others ( $0.23 < R^2_{\text{adj}} < 0.77$ ). IGE and schizotypy show low and non-significant correspondence with receptor distributions, whereas ADHD, autism and temporal lobe epilepsies show greater correspondence with receptor distributions. The dominance analysis in Fig. 6b shows the contribution of each input variable to the fit of the model, normalized by the total fit (adjusted  $R^2$ ). Interestingly, we found that serotonin transporter (5-HTT) distributions contribute more to OCD, schizophrenia and BD profiles than any other receptors. Furthermore, the mu-opioid receptor is the strongest contributor of ADHD cortical abnormalities, consistent with findings from animal models<sup>36</sup>. We also note that, in some cases, the analyses do not necessarily recover the expected relationships. For instance, in PD, the dopamine receptors are not implicated, likely because the analysis was restricted to cortex only. Additionally, serotonin receptors do not make large contributions to depression, possibly because changes in cortical thickness do not directly measure the primary pathophysiology associated with some brain diseases. Although this analysis points to mappings between receptors and disorder profiles, we found no

significant differential contribution of receptor classes to disorder profiles (Supplementary Fig. 5c). Our results present an initial step toward a comprehensive ‘look-up table’ that relates neurotransmitter systems to multiple brain disorders.

### Replication using autoradiography

In the present report, we comprehensively situate neurotransmitter receptor and transporter densities within the brain's structural and functional architecture. However, estimates for neurotransmitter receptor densities are acquired from PET imaging alone, and the way in which densities are quantified varies across radioligands, image acquisition protocols and pre-processing. Autoradiography is an alternative technique to measure receptor density and captures local densities at a defined number of postmortem brain sections. Due to the high cost and labor intensity of acquiring autoradiographs, there does not yet exist a complete autoradiography three-dimensional (3D) cross-cortex atlas of receptors.

Nonetheless, we repeated the analyses in an autoradiography dataset of 15 neurotransmitter receptors across 44 cytoarchitectonically defined cortical areas, from three postmortem brains<sup>6,37</sup>. This set of 15 neurotransmitter receptors consists of a diverse set of ionotropic



**Fig. 4 | Receptor profiles shape oscillatory neural dynamics.** We fit a multi-linear regression model that predicts MEG-derived power distributions from receptor distributions. **a**, Receptor distributions closely correspond to all six MEG-derived power bands ( $0.78 \leq R^2_{\text{adj}}(80) \leq 0.94$ ). The significance of each model is assessed against a spatial permutation-preserving null model and corrected for multiple comparisons (FDR correction). Asterisks denote significant models (FDR-corrected  $P_{\text{spin}} < 0.05$ , one-tailed). Delta  $R^2_{\text{adj}}(80) = 0.89$ ,  $P_{\text{spin}} = 0.03$ ; theta  $R^2_{\text{adj}}(80) = 0.94$ ,  $P_{\text{spin}} = 0.0006$ ; alpha  $R^2_{\text{adj}}(80) = 0.93$ ,

$P_{\text{spin}} = 0.0006$ ; beta  $R^2_{\text{adj}}(80) = 0.84$ ,  $P_{\text{spin}} = 0.008$ ; low-gamma  $R^2_{\text{adj}}(80) = 0.83$ ,  $P_{\text{spin}} = 0.04$ ; and high-gamma  $R^2_{\text{adj}}(80) = 0.78$ ,  $P_{\text{spin}} = 0.16$ . **b**, Dominance analysis distributes the fit of the model across input variables such that the contribution of each variable can be assessed and compared to other input variables. The percent contribution of each input variable is defined as the variable's dominance normalized by the total fit ( $R^2_{\text{adj}}$ ) of the model. Note that dominance analysis is not applied to the input variables of non-significant models (that is, high-gamma).

and metabotropic receptors, including excitatory glutamate, acetylcholine and norepinephrine receptors (see Supplementary Table 1 for a complete list of receptors). Notably, eight of the 15 receptors in the autoradiography dataset are not included in the PET dataset, which precludes direct comparisons between the two datasets. Receptor similarity is shown in Supplementary Fig. 8a. Despite the alternate set of neurotransmitter receptors, we found that autoradiography-derived receptor similarity is significantly correlated with PET-derived receptor similarity (Pearson's  $r(1033) = 0.38$ ,  $P = 6.7 \times 10^{-38}$ ,  $\text{CI} = [0.33, 0.44]$ ; Supplementary Fig. 8a) and decays exponentially with Euclidean distance. Additionally, autoradiography-derived and PET-derived receptor gradients are correlated (Pearson's  $r(44) = 0.51$ ,  $P_{\text{perm}} = 0.0001$ ,  $\text{CI} = [0.26, 0.70]$ , two-sided). Next, we found that autoradiography-derived receptor densities follow similar architectural patterns as the PET-derived receptor densities. Receptor similarity is non-significantly greater between structurally connected brain regions ( $P = 0.19$ ) and significantly correlated with structural connectivity (Pearson's  $r(329) = 0.39$ ,  $P = 1.4 \times 10^{-13}$ ,  $\text{CI} = [0.30, 0.48]$ ; Supplementary Fig. 8d). It is also significantly greater in regions within the same intrinsic network ( $P_{\text{spin}} = 0.03$ ) and is significantly correlated with functional connectivity (Pearson's  $r(1033) = 0.21$ ,  $P = 1.1 \times 10^{-12}$ ,  $\text{CI} = [0.16, 0.28]$ ; Supplementary Fig. 8e). As before, receptor information augments structure–function coupling in visual, paracentral and somatomotor regions (Supplementary Fig. 8f). Finally, we show correlations of receptor density distribution between every pair of receptors in Supplementary Fig. 8g.

Because the autoradiography dataset has a more diverse set of ionotropic and metabotropic receptors, we also asked whether we would observe a prominence of ionotropic receptors for MEG oscillations. When we fit the 15 autoradiography neurotransmitter receptors to MEG power, we found that AMPA, NMDA, GABA<sub>A</sub> and  $\alpha_4\beta_2$ —all ionotropic receptors—are most dominant (Supplementary Fig. 4). This confirms that the fast oscillatory dynamics captured by MEG are closely related to the fluctuations in neural activity modulated by ionotropic neurotransmitter receptors.

Finally, we repeated analyses mapping receptor densities to cognitive functional activation and disease vulnerability. We found a similar topographic gradient linking autoradiography-derived


receptor densities to Neurosynth-derived functional activations (Supplementary Fig. 9a). Indeed, PET-derived and autoradiography-derived receptor and cognitive scores are correlated (Supplementary Fig. 8b; Pearson's  $r = -0.50$ ,  $P_{\text{perm}} = 0.0002$ ,  $\text{CI} = [-0.69, -0.26]$  for receptor scores; Pearson's  $r = -0.75$ ,  $P_{\text{perm}} = 0.0001$ ,  $\text{CI} = [-0.86, -0.60]$  for cognitive scores). We also found consistencies regarding the loadings of receptors (Supplementary Fig. 9c) and cognitive processes (Supplementary Fig. 9d). Next, when we mapped autoradiography-derived receptor densities to cortical abnormality patterns of multiple disorders, we found prominent associations with receptors that were not included in the PET dataset, including a relationship between the ionotropic glutamate receptor kainate and depression (Supplementary Fig. 10).

### Sensitivity and robustness analyses

Finally, to ensure that results are not influenced by specific methodological choices, we repeated analyses using different parcellation resolutions and different receptor subsets, and we compared alternative PET tracers to the chosen PET tracers in the present report. Due to the low spatial resolution of PET tracer binding, we opted to present our main results using a coarse resolution of 100 cortical regions<sup>12</sup>. However, when using a parcellation resolution of 200 and 400 cortical regions, we found that the mean receptor density and receptor similarity remains consistent (Supplementary Fig. 11). We next asked whether any single receptor or transporter disproportionately influences receptor similarity. To test this, we iteratively removed a single receptor/transporter from the dataset and recomputed the receptor similarity matrix. These 19 different receptor similarity matrices are all highly correlated with the original similarity matrix (Pearson's  $r(4948) > 0.98$ ), confirming that the correspondence between regional receptor profiles is not driven by a single neurotransmitter receptor/transporter.

We also tested whether participant age affects the reported results. However, only mean age of individuals included in each tracer map was available. Therefore, we fit a linear model between the mean age of scanned participants contributing to each receptor/transporter tracer map and the z-scored receptor/transporter density, for each





**Fig. 5 | Mapping receptors to cognitive function.** **a**, Using PLS analysis, we found a significant latent variable that accounts for 54% of the covariation between receptor distributions and Neurosynth-derived cognitive functional activation ( $P_{\text{spin}} = 0.010$ , 10,000 repetitions, one-sided). **b, c**, This latent variable represents a pattern of co-activation between receptors ('receptor scores') and cognitive terms ('cognitive scores'). **d**, The PLS model was cross-validated using a method that stratifies the training set (yellow points) and test set (gray points) based on the distance between each node to a source node (red point), and the procedure is repeated such that each brain region is assigned as the source node once (100 repetitions). The significance of the mean out-of-sample test set correlation was assessed against a null distribution of mean correlation constructed by rotating the receptor density matrix before the PLS analysis (see Methods for details). **e**, Receptor loadings are computed as the

correlation (Pearson's  $r$ ) between each receptor's distribution across the cortex and the PLS-derived scores and can be interpreted as the contribution of each receptor to the latent variable. **f**, Similarly, cognitive loadings are computed as the correlation (Pearson's  $r$ ) between each term's functional activation across brain regions and the PLS-derived scores and can be interpreted as the cognitive processes that contribute most to the latent variable. Here, only the 25% most positively and negatively loaded cognitive processes are shown. For all stable cognitive loadings, see Supplementary Fig. 6, and, for all 123 cognitive processes included in the analysis, see Supplementary Table 2. Bounds of the box plots in **a** and **d** represent the 1st (25%) and 3rd (75%) quartiles; the center line represents the median; whiskers represent the non-outlier minima and maxima of the distribution; and open circles represent outliers.

brain region separately. We then subtracted the relationship with age from the original receptor densities, resulting in an age-regressed receptor density matrix. We found that both age-regressed receptor density and age-regressed receptor similarity is highly correlated with the original receptor density/similarity (Pearson's  $r(4948) = 0.78$ ,  $P = 0$ ,  $CI = [0.76, 0.79]$  and Pearson's  $r(4948) = 0.984$ ,  $P = 0$ ,  $CI = [0.982, 0.985]$ , respectively; Supplementary Fig. 12), suggesting that age has a negligible effect on the reported findings. However, we note that this analysis is not sensitive to individual subject variability and that certain neurotransmitter receptor systems show changes in receptor availability with age<sup>38–40</sup>.


## Discussion

In the present report, we curate a comprehensive 3D atlas of 19 neurotransmitter receptors and transporters. We demonstrate that chemoarchitecture is a key layer of the multi-scale organization of the brain. Neurotransmitter receptor profiles closely align with the structural connectivity of the brain and mediate its link with function, including neurophysiological oscillatory dynamics and resting-state hemodynamic functional connectivity. The overlapping topographic distributions of these receptors ultimately manifest as patterns of cognitive specialization and disease vulnerability.

A key question in neuroscience remains how the brain's structural architecture gives rise to its function<sup>41</sup>. The relationship between whole-brain structure and function has been viewed through the lens of 'connectomics', in which the brain's structural or functional architectures are represented by regional nodes interconnected by structural and functional links. The key assumption of this model is that nodes are homogenous, effectively abstracting away important microarchitectural differences between regions. The present work is part of an emerging effort to annotate the connectome with molecular, cellular and laminar attributes. Indeed, recent work has incorporated microarray gene transcription<sup>28</sup>, cell types<sup>42</sup>, myelination<sup>19</sup>, laminar differentiation<sup>43</sup> and intrinsic dynamics<sup>44</sup> into structural and functional models of the brain.

Neurotransmitter receptors and transporters are an important molecular annotation for bridging brain structure to brain function. Despite this, a comprehensive cortical map of neurotransmitter receptors has remained elusive due to numerous methodological and data-sharing challenges (but see the ongoing PET-BIDS effort as well as the OpenNeuro PET initiative at <https://openneuropet.github.io/> (refs.<sup>10,11</sup>)). The present study is an ongoing Open Science grassroots effort to assemble harmonized high-resolution normative images of receptors and transporters that can be used to annotate connectomic models





**Fig. 6 | Mapping receptors to disease vulnerability.** Using a multi-linear model, neurotransmitter receptor/transporter distributions were fit to patterns of cortical abnormality for 13 neurological, psychiatric and neurodevelopmental disorders, collected by the ENIGMA consortium. **a**, The significance of each model is assessed using a spatial autocorrelation-preserving null model and is corrected for multiple comparisons (FDR). Asterisks denote significant models (FDR-corrected  $P_{\text{spin}} < 0.05$ , one-sided). 22q11.2 deletion  $R^2_{\text{adj}}(48) = 0.50$ ,  $P_{\text{spin}} = 0.02$ ; ADHD  $R^2_{\text{adj}}(48) = 0.67$ ,  $P_{\text{spin}} = 0.02$ ; autism  $R^2_{\text{adj}}(48) = 0.77$ ,  $P_{\text{spin}} = 0.02$ ; epilepsy (IGE)  $R^2_{\text{adj}}(48) = 0.23$ ,  $P_{\text{spin}} = 0.17$ ; epilepsy (right)  $R^2_{\text{adj}}(48) = 0.70$ ,  $P_{\text{spin}} = 0.02$ ; epilepsy (left)  $R^2_{\text{adj}}(48) = 0.58$ ,  $P_{\text{spin}} = 0.02$ ; depression  $R^2_{\text{adj}}(48) = 0.69$ ,  $P_{\text{spin}} = 0.01$ ; OCD  $R^2_{\text{adj}}(48) = 0.29$ ,  $P_{\text{spin}} = 0.02$ ;

schizophrenia  $R^2_{\text{adj}}(48) = 0.52$ ,  $P_{\text{spin}} = 0.02$ ; BD  $R^2_{\text{adj}}(48) = 0.56$ ,  $P_{\text{spin}} = 0.01$ ; obesity  $R^2_{\text{adj}}(48) = 0.58$ ,  $P_{\text{spin}} = 0.02$ ; schizotypy  $R^2_{\text{adj}}(48) = 0.29$ ,  $P_{\text{spin}} = 0.32$ ; and PD  $R^2_{\text{adj}}(48) = 0.55$ ,  $P_{\text{spin}} = 0.02$ . **b**, Dominance analysis distributes the fit of the model across input variables such that the contribution of each variable can be assessed and compared to other input variables. The percent contribution of each input variable is defined as the variable's dominance normalized by the total fit ( $R^2_{\text{adj}}$ ) of the model. Note that dominance analysis is not applied to the input variables of non-significant models (that is, IGE and schizotypy) and that this analysis is conducted using the Desikan–Killiany atlas because this is the only representation of ENIGMA datasets.

of the brain. This work builds on previous initiatives to map receptor densities using autoradiography, which has discovered prominent gradients of receptor expression in both human and macaque brains<sup>6,20,37</sup>. Notably, we found consistent results between autoradiography and PET datasets, which is encouraging because the PET dataset consists of a different group of receptors and transporters and has the added advantage of providing in vivo whole-brain data in large samples of healthy young participants.

We found a prominent link between receptor distribution and both brain structure and function, which supports the idea that the emergent functional architecture strongly depends on the underlying chemoarchitecture<sup>4</sup>. Interestingly, we found that the canonical electrophysiological frequency bands can be captured by the overlapping topographies of multiple receptors, consistent with the notion that receptors influence function by tuning gain and synchrony between neuronal populations<sup>45</sup>. Because receptors are correlated with multiple features of brain structure and function, a natural next question is how receptor distributions relate to psychological processes. We found a

multivariate mapping between receptor profiles and cognitive activations. Interestingly, although individual receptors have been associated with specific functions (for example, D1 and selective attention<sup>46</sup>), our findings suggest that the combined spatial distribution of serotonergic and dopaminergic receptors underlie patterns of cognitive activation related to affect. Altogether, these results offer clues about how multiple neurotransmitter systems collectively influence cognitive functions and present novel hypotheses that future causal studies can test.

Finally, we discovered a robust spatial concordance between multiple receptor maps and cortical abnormality profiles across a wide range of brain disorders. A key step toward developing therapies for specific syndromes is to reliably map them onto underlying neural systems. This goal is challenging because psychiatric and neurological nosology is built around clinical features rather than neurobiological mechanisms. Our results complement some previously established associations between disorders and neurotransmitter systems and also reveal new associations. For instance, we found that the serotonin transporter is the strongest contributor to schizophrenia and BD, consistent with

the fact that mood disorders are often accompanied with abnormal serotonin signaling<sup>47,48</sup>. On the other hand, we found associations that have some preliminary support in the literature but, to our knowledge, have not been conclusively established and adopted into clinical practice, including histamine H<sub>3</sub> in PD<sup>49</sup>, MOR in ADHD<sup>36</sup> and D<sub>1</sub> and NET in temporal lobe epilepsy<sup>50,51</sup>. Mapping disease phenotypes to receptor profiles will help to identify novel targets for pharmacotherapy. This analysis is restricted to a single perspective of disease pathology (cortical thinning/thickening) and should be expanded in future work to encompass other forms of disease presentation as well as the effects of age and pathology on receptor/transporter density.

Collectively, the main results in the present report aim to go beyond traditional one-to-one (that is, univariate) associations between receptors and brain function, toward considering how multiple neurotransmitter systems work together. The present report builds on the theories generated by previous neurochemical and pharmacological causal studies, and it is encouraging to see consistent results at the level of the whole brain, across multiple neurotransmitter systems and using different imaging modalities. Furthermore, the comprehensive approach of this study showcases novel associations that may not have been considered before. This large-scale characterization of receptor systems should be validated in, and will hopefully inspire, future causal studies, driving the cycle of discovery. Altogether, our data and analyses provide a framework that allows us to test predictions from the wider literature and consolidate knowledge about neurotransmitter systems.

Some potential avenues for future complementary research are to study how receptor architecture changes in healthy aging, across the sexes, and how they map onto subcortical structures. Indeed, dopamine D1 and D2 receptor availability is commonly acknowledged to decrease with age in the subcortex<sup>38</sup>; serotonin transporter and receptor density have been reported to be significantly lower in older adults<sup>39</sup>; and GABA<sub>A</sub> density is reported to be higher in older adults<sup>40</sup>. Likewise, previously published literature has reported greater whole-brain glutamate receptor densities in men<sup>52</sup>, greater kappa-opioid receptor density in men<sup>53</sup> and greater mu-opioid receptor density in women<sup>54</sup>. Finally, multiple neurotransmitter projection systems originate in the subcortex<sup>1</sup>, and neurodegenerative disease progression has been linked with abnormal subcortical receptor expression<sup>55</sup>. Ultimately, future research is necessary to characterize multi-system receptor distributions across age and sex and within subcortical structures.

The present work should be considered alongside some important methodological considerations. First, main analyses were conducted using PET images, which detect tracer uptake at a low spatial resolution and without laminar specificity. Although results were replicated using an autoradiography dataset, and in a finer parcellation resolution, a comprehensive atlas of laminar-resolved receptor density measurements is necessary to fully understand how regional variations in receptor densities affect brain structure and function<sup>21</sup>. Second, PET tracer maps were acquired around the world, in different participants, on different scanners and using specific image acquisition and processing protocols recommended for each individual radioligand<sup>56,57</sup>. To mitigate this challenge, we normalized the spatial distributions and focused only on analyses related to the relative spatial topographies of receptors as opposed to the absolute values. Third, the linear models used in the present analyses assume independence between observations and linear relationships between receptors; we, therefore, employed spatial autocorrelation-preserving null models to account for the spatial dependencies between regions throughout the report. Fourth, analyses were restricted to the cortex, obscuring the contributions of subcortical neuromodulatory systems. Fifth, although we repeated our analyses in an autoradiography dataset, eight of the 15 receptors included in the autoradiography dataset are not included in the PET datasets, and, therefore, a direct comparison between datasets was not

possible. Altogether, a 3D whole-brain comprehensive neurotransmitter receptor density dataset constructed using autoradiographs would be a valuable complement to the present work<sup>6,21</sup>.

In summary, we assembled a normative 3D atlas of neurotransmitter receptors in the human brain. We systematically mapped receptors to connectivity, dynamics, cognitive specialization and disease vulnerability. Our work uncovers a fundamental organizational feature of the brain and provides new direction for a multi-scale systems-level understanding of brain structure and function.

## Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41593-022-01186-3>.

## References

- Shine, J. M. Neuromodulatory influences on integration and segregation in the brain. *Trends Cogn. Sci.* **23**, 572–583 (2019).
- Sporns, O. & Betzel, R. F. Modular brain networks. *Annu. Rev. Psychol.* **67**, 613–640 (2016).
- Van den Heuvel, M. P., Bullmore, E. T. & Sporns, O. Comparative connectomics. *Trends Cogn. Sci.* **20**, 345–361 (2016).
- Zilles, K., Bacha-Trams, M., Palomero-Gallagher, N., Amunts, K. & Friederici, A. D. Common molecular basis of the sentence comprehension network revealed by neurotransmitter receptor fingerprints. *Cortex* **63**, 79–89 (2015).
- Kringelbach, M. L. et al. Dynamic coupling of whole-brain neuronal and neurotransmitter systems. *Proc. Natl Acad. Sci. USA* **117**, 9566–9576 (2020).
- Zilles, K. & Palomero-Gallagher, N. Multiple transmitter receptors in regions and layers of the human cerebral cortex. *Front. Neuroanat.* **11**, 78 (2017).
- Dukart, J. et al. JuSpace: a tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. *Hum. Brain Mapp.* **42**, 555–566 (2021).
- Nørgaard, M. et al. A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABA<sub>A</sub> receptors. *Neuroimage* **232**, 117878 (2021).
- Beliveau, V. et al. A high-resolution in vivo atlas of the human brain's serotonin system. *J. Neurosci.* **37**, 120–128 (2017).
- Knudsen, G. M. et al. Guidelines for the content and format of PET brain data in publications and archives: a consensus paper. *J. Cereb. Blood Flow Metab.* **40**, 1576–1585 (2020).
- Nørgaard, M. et al. PET-BIDS, an extension to the brain imaging data structure for positron emission tomography. *Sci. Data* **9**, 65 (2022). <https://www.nature.com/articles/s41597-022-01164-1>
- Schaefer, A. et al. Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. *Cereb. Cortex* **28**, 3095–3114 (2018).
- Evans, A. C. Networks of anatomical covariance. *Neuroimage* **80**, 489–504 (2013).
- Seidlitz, J. et al. Morphometric similarity networks detect microscale cortical organization and predict inter-individual cognitive variation. *Neuron* **97**, 231–247 (2018).
- Arnatkeviciute, A., Fulcher, B., Bellgrove, M. & Fornito, A. Where the genome meets the connectome: understanding how genes shape human brain connectivity. *Neuroimage* **244**, 118570 (2021).
- Shafiei, G. et al. Topographic gradients of intrinsic dynamics across neocortex. *eLife* **9**, e62116 (2020).
- Paquola, C. et al. Microstructural and functional gradients are increasingly dissociated in transmodal cortices. *PLoS Biol.* **17**, e3000284 (2019).

18. Hilgetag, C. C., Goulas, A. & Changeux, J.-P. A natural cortical axis connecting the outside and inside of the human brain. *Netw. Neurosci.* [https://doi.org/10.1162/netn\\_a\\_00256](https://doi.org/10.1162/netn_a_00256) (2022).
19. Huntenburg, J. M. et al. A systematic relationship between functional connectivity and intracortical myelin in the human cerebral cortex. *Cereb. Cortex* **27**, 981–997 (2017).
20. Froudust-Walsh, S. et al. Gradients of receptor expression in the macaque cortex. Preprint at <https://www.biorxiv.org/content/10.1101/2021.02.22.432173v1> (2021).
21. Palomero-Gallagher, N. & Zilles, K. Cortical layers: cyto-, myelo-, receptor- and synaptic architecture in human cortical areas. *Neuroimage* **197**, 716–741 (2019).
22. Betzel, R. F. & Bassett, D. S. Specificity and robustness of long-distance connections in weighted, interareal connectomes. *Proc. Natl Acad. Sci. USA* **115**, E4880–E4889 (2018).
23. Yeo, B. et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *J. Neurophysiol.* **106**, 1125–1165 (2011).
24. Alexander-Bloch, A. F. et al. On testing for spatial correspondence between maps of human brain structure and function. *Neuroimage* **178**, 540–551 (2018).
25. Markello, R. D. & Misisic, B. Comparing spatial null models for brain maps. *Neuroimage* **236**, 118052 (2021).
26. Crofts, J. J. & Higham, D. J. A weighted communicability measure applied to complex brain networks. *J. R. Soc. Interface* **6**, 411–414 (2009).
27. Seguin, C., Sporns, O., Zalesky, A. & Calamante, F. Network communication models narrow the gap between the modular organization of structural and functional brain networks. *Neuroimage* **257**, 119323 (2022).
28. Hansen, J. Y. et al. Mapping gene transcription and neurocognition across human neocortex. *Nat. Hum. Behav.* **5**, 1240–1250 (2021).
29. Van Essen, D. C. et al. The Wu-Minn Human Connectome Project: an overview. *Neuroimage* **80**, 62–79 (2013).
30. Shafiei, G., Baillet, S. & Misisic, B. Human electromagnetic and haemodynamic networks systematically converge in unimodal cortex and diverge in transmodal cortex. *PLoS Biol.* **20**, e3001735 (2022).
31. Azen, R. & Budescu, D. V. The dominance analysis approach for comparing predictors in multiple regression. *Psychol. Methods* **8**, 129–148 (2003).
32. Ploner, M., Sorg, C. & Gross, J. Brain rhythms of pain. *Trends Cogn. Sci.* **21**, 100–110 (2017).
33. Witjes, B. et al. Magnetoencephalography reveals increased slow-to-fast alpha power ratios in patients with chronic pain. *Pain Rep.* **6**, e928 (2021).
34. Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C. & Wager, T. D. Large-scale automated synthesis of human functional neuroimaging data. *Nat. Methods* **8**, 665–670 (2011).
35. Ruhé, H. G., Mason, N. S. & Schene, A. H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. *Mol. Psychiatry* **12**, 331–359 (2007).
36. Sagvolden, T. et al. The spontaneously hypertensive rat model of ADHD—the importance of selecting the appropriate reference strain. *Neuropharmacology* **57**, 619–626 (2009).
37. Goulas, A. et al. The natural axis of transmitter receptor distribution in the human cerebral cortex. *Proc. Natl Acad. Sci. USA* **118**, e2020574118 (2021).
38. Seaman, K. L. et al. Differential regional decline in dopamine receptor availability across adulthood: linear and nonlinear effects of age. *Hum. Brain Mapp.* **40**, 3125–3138 (2019).
39. Karrer, T. M., McLaughlin, C. L., Guaglianone, C. P. & Samanez-Larkin, G. R. Reduced serotonin receptors and transporters in normal aging adults: a meta-analysis of PET and SPECT imaging studies. *Neurobiol. Aging* **80**, 1–10 (2019).
40. Cuypers, K. et al. Age-related GABAergic differences in the primary sensorimotor cortex: a multimodal approach combining PET, MRS and TMS. *Neuroimage* **226**, 117536 (2021).
41. Suárez, L. E., Markello, R. D., Betzel, R. F. & Misisic, B. Linking structure and function in macroscale brain networks. *Trends Cogn. Sci.* **24**, 302–315 (2020).
42. Seidlitz, J. et al. Transcriptomic and cellular decoding of regional brain vulnerability to neurodevelopmental disorders. *Nat. Commun.* **11**, 3358 (2020).
43. Wagstyl, K. et al. BigBrain 3D atlas of cortical layers: cortical and laminar thickness gradients diverge in sensory and motor cortices. *PLoS Biol.* **18**, e3000678 (2020).
44. Gao, R., van den Brink, R. L., Pfeffer, T. & Voytek, B. Neuronal timescales are functionally dynamic and shaped by cortical microarchitecture. *eLife* **9**, e61277 (2020).
45. Shine, J. M. et al. Computational models link cellular mechanisms of neuromodulation to large-scale neural dynamics. *Nat. Neurosci.* **24**, 765–776 (2021).
46. Noudoost, B. & Moore, T. The role of neuromodulators in selective attention. *Trends Cogn. Sci.* **15**, 585–591 (2011).
47. Kato, T. Current understanding of bipolar disorder: toward integration of biological basis and treatment strategies. *Psychiatry Clin. Neurosci.* **73**, 526–540 (2019).
48. Stępnicki, P., Kondej, M. & Kaczor, A. A. Current concepts and treatments of schizophrenia. *Molecules* **23**, 2087 (2018).
49. Rinne, J. et al. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. *J. Neurochem.* **81**, 954–960 (2002).
50. Costa, C. et al. Epilepsy, amyloid- $\beta$ , and D1 dopamine receptors: a possible pathogenetic link? *Neurobiol. Aging* **48**, 161–171 (2016).
51. Giorgi, F. S., Pizzanelli, C., Biagioni, F., Murri, L. & Fornai, F. The role of norepinephrine in epilepsy: from the bench to the bedside. *Neurosci. Biobehav. Rev.* **28**, 507–524 (2004).
52. Smart, K. et al. Sex differences in [ $^{11}\text{C}$ ]ABP688 binding: a positron emission tomography study of mglu5 receptors. *Eur. J. Nucl. Med. Mol. Imaging* **46**, 1179–1183 (2019).
53. Vijay, A. et al. PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. *Am. J. Nucl. Med. Mol. Imaging* **6**, 205–214 (2016).
54. Zubieta, J.-K., Dannals, R. F. & Frost, J. J. Gender and age influences on human brain mu-opioid receptor binding measured by PET. *Am. J. Psychiatry* **156**, 842–848 (1999).
55. Leko, M. B., Hof, P. R. & Šimić, G. Alterations and interactions of subcortical modulatory systems in Alzheimer's disease. *Prog. Brain Res.* **261**, 379–421 (2021).
56. Nørgaard, M. et al. Optimization of preprocessing strategies in positron emission tomography (PET) neuroimaging: a [ $^{11}\text{C}$ ]DASB PET study. *Neuroimage* **199**, 466–479 (2019).
57. Veronese, M. et al. Reproducibility of findings in modern PET neuroimaging: insight from the NRM2018 grand challenge. *J. Cereb. Blood Flow Metab.* **41**, 2778–2796 (2021).
58. Kaller, S. et al. Test–retest measurements of dopamine D<sub>1</sub>-type receptors using simultaneous PET/MRI imaging. *Eur. J. Nucl. Med. Mol. Imaging* **44**, 1025–1032 (2017).
59. Smith, C. T. et al. Partial-volume correction increases estimated dopamine D2-like receptor binding potential and reduces adult age differences. *J. Cereb. Blood Flow Metab.* **39**, 822–833 (2019).
60. Sandiego, C. M. et al. Reference region modeling approaches for amphetamine challenge studies with [ $^{11}\text{C}$ ]FLB457 and PET. *J. Cereb. Blood Flow Metab.* **35**, 623–629 (2015).
61. Zakiniaez, Y. et al. Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. *Neuropsychopharmacology* **44**, 2205–2211 (2019).



62. Slifstein, M. et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. *JAMA Psychiatry* **72**, 316–324 (2015).
63. Sandiego, C. M. et al. The effect of treatment with guanfacine, an  $\alpha_2$  adrenergic agonist, on dopaminergic tone in tobacco smokers: an [ $^{11}\text{C}$ ]FLB457 PET study. *Neuropsychopharmacology* **43**, 1052–1058 (2018).
64. Dukart, J. et al. Cerebral blood flow predicts differential neurotransmitter activity. *Sci. Rep.* **8**, 4074 (2018).
65. Ding, Y.-S. et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[ $^{11}\text{C}$ ] O-methylreboxetine and HRRT. *Synapse* **64**, 30–38 (2010).
66. Chiang-shan, R. L. et al. Decreased norepinephrine transporter availability in obesity: positron emission tomography imaging with (S,S)-[ $^{11}\text{C}$ ] O-methylreboxetine. *Neuroimage* **86**, 306–310 (2014).
67. Sanchez-Rangel, E. et al. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [ $^{11}\text{C}$ ] MRB. *Int. J. Obes. (Lond)*. **44**, 964–967 (2020).
68. Belfort-DeAguiar, R. et al. Noradrenergic activity in the human brain: a mechanism supporting the defense against hypoglycemia. *J. Clin. Endocrinol. Metab.* **103**, 2244–2252 (2018).
69. Savli, M. et al. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. *Neuroimage* **63**, 447–459 (2012).
70. Gallezot, J.-D. et al. Kinetic modeling of the serotonin 5-HT<sub>1B</sub> receptor radioligand [ $^{11}\text{C}$ ]P943 in humans. *J. Cereb. Blood Flow Metab.* **30**, 196–210 (2010).
71. Murrough, J. W. et al. Reduced ventral striatal/ventral pallidal serotonin<sub>1B</sub> receptor binding potential in major depressive disorder. *Psychopharmacology* **213**, 547–553 (2011).
72. Murrough, J. W. et al. The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. *Arch. Gen. Psychiatry* **68**, 892–900 (2011).
73. Matuskey, D. et al. Reductions in brain 5-HT<sub>1B</sub> receptor availability in primarily cocaine-dependent humans. *Biol. Psychiatry* **76**, 816–822 (2014).
74. Pittenger, C. et al. OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT<sub>1B</sub> receptor binding. *J. Affect. Disord.* **196**, 87–96 (2016).
75. Saricicek, A. et al. Test–retest reliability of the novel 5-HT<sub>1B</sub> receptor PET radioligand [ $^{11}\text{C}$ ]P943. *Eur. J. Nucl. Med. Mol. Imaging* **42**, 468–477 (2015).
76. Baldassarri, S. R. et al. Inverse changes in raphe and cortical 5-HT<sub>1B</sub> receptor availability after acute tryptophan depletion in healthy human subjects. *Synapse* **74**, e22159 (2020).
77. Radhakrishnan, R. et al. Age-related change in 5-HT<sub>6</sub> receptor availability in healthy male volunteers measured with  $^{11}\text{C}$ -GSK215083 PET. *J. Nucl. Med.* **59**, 1445–1450 (2018).
78. Radhakrishnan, R. et al. In vivo 5-HT<sub>6</sub> and 5-HT<sub>2A</sub> receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [ $^{11}\text{C}$ ]GSK215083 PET. *Psychiatry Res. Neuroimaging* **295**, 111007 (2020).
79. Hillmer, A. T. et al. Imaging of cerebral  $\alpha_4\beta_2^*$  nicotinic acetylcholine receptors with (–)-[ $^{18}\text{F}$ ]flubatine PET: implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. *Neuroimage* **141**, 71–80 (2016).
80. Baldassarri, S. R. et al. Use of electronic cigarettes leads to significant beta2-nicotinic acetylcholine receptor occupancy: evidence from a PET imaging study. *Nicotine Tob. Res.* **20**, 425–433 (2018).
81. Naganawa, M. et al. First-in-human assessment of  $^{11}\text{C}$ -LSN3172176, an M1 muscarinic acetylcholine receptor PET radiotracer. *J. Nucl. Med.* **62**, 553–560 (2021).
82. Aghourian, M. et al. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [ $^{18}\text{F}$ ]-FEOBV. *Mol. Psychiatry* **22**, 1531–1538 (2017).
83. Bedard, M.-A. et al. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with  $^{18}\text{F}$ -FEOBV. *Sleep Med.* **58**, 35–41 (2019).
84. Galovic, M. et al. In vivo NMDA receptor function in people with NMDA receptor antibody encephalitis. Preprint at <https://www.medrxiv.org/content/10.1101/2021.12.04.21267226v1> (2021).
85. Galovic, M. et al. Validation of a combined image derived input function and venous sampling approach for the quantification of [ $^{18}\text{F}$ ]GE-179 PET binding in the brain. *Neuroimage* **237**, 118194 (2021).
86. McGinnity, C. J. et al. Initial evaluation of  $^{18}\text{F}$ -GE-179, a putative PET tracer for activated N-methyl D-aspartate receptors. *J. Nucl. Med.* **55**, 423–430 (2014).
87. DuBois, J. M. et al. Characterization of age/sex and the regional distribution of mglur5 availability in the healthy human brain measured by high-resolution [ $^{11}\text{C}$ ]ABP688 PET. *Eur. J. Nucl. Med. Mol. Imaging* **43**, 152–162 (2016).
88. Gallezot, J.-D. et al. Determination of receptor occupancy in the presence of mass dose: [ $^{11}\text{C}$ ]GSK189254 PET imaging of histamine H<sub>3</sub> receptor occupancy by PF-03654746. *J. Cereb. Blood Flow Metab.* **37**, 1095–1107 (2017).
89. Normandin, M. D. et al. Imaging the cannabinoid CB1 receptor in humans with [ $^{11}\text{C}$ ]OMAR: assessment of kinetic analysis methods, test–retest reproducibility, and gender differences. *J. Cereb. Blood Flow Metab.* **35**, 1313–1322 (2015).
90. D'Souza, D. C. et al. Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* **1**, 60–67 (2016).
91. Ranganathan, M. et al. Reduced brain cannabinoid receptor availability in schizophrenia. *Biol. Psychiatry* **79**, 997–1005 (2016).
92. Neumeister, A. et al. Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. *Alcohol. Clin. Exp. Res.* **36**, 2104–2109 (2012).
93. Kantonen, T. et al. Interindividual variability and lateralization of  $\mu$ -opioid receptors in the human brain. *Neuroimage* **217**, 116922 (2020).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

<sup>1</sup>Montréal Neurological Institute, McGill University, Montréal, QC, Canada. <sup>2</sup>Yale PET Center, Yale School of Medicine, New Haven, CT, USA. <sup>3</sup>Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. <sup>4</sup>Department of Psychiatry, McGill University, Montréal, QC, Canada. <sup>5</sup>Department of Psychology, Center for Reproducible Neuroscience, Stanford University, Stanford, CA, USA. <sup>6</sup>Neurobiology Research Unit, Cimbi & OpenNeuroPET, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. <sup>7</sup>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. <sup>8</sup>Cognitive Pharmacology Research Unit, UQAM, Montréal, QC, Canada. <sup>9</sup>McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montréal, QC, Canada. <sup>10</sup>Biogen Inc., Cambridge, MA, USA. <sup>11</sup>Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia. <sup>12</sup>Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany. <sup>13</sup>Department of Physiology and Pharmacology, University of Western Ontario, London, ON, Canada. <sup>14</sup>Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland. <sup>15</sup>Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK. <sup>16</sup>MRI Unit, Chalfont Centre for Epilepsy, Chalfont Saint Peter, UK. <sup>17</sup>Department of Medicine, Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. <sup>18</sup>Department of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. <sup>19</sup>King's College London and Guy's and St. Thomas' PET Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK. <sup>20</sup>Department of Psychiatry, Royal's Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada. <sup>21</sup>Department of Psychoeducation and Psychology, University of Quebec in Outaouais, Gatineau, QC, Canada. <sup>22</sup>Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland. <sup>23</sup>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. <sup>24</sup>C. and O. Vogt Institute for Brain Research, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.

✉ e-mail: [bratislav.misic@mcgill.ca](mailto:bratislav.misic@mcgill.ca)

## Methods

All code and data used to perform the analyses can be found at [https://github.com/netneurolab/hansen\\_receptors](https://github.com/netneurolab/hansen_receptors). Volumetric PET images are included in neuromaps (<https://github.com/netneurolab/neuromaps>) where they can be easily converted between template spaces<sup>94</sup>.

### PET data acquisition

Volumetric PET images were collected for 19 different neurotransmitter receptors and transporters across multiple studies. To protect patient confidentiality, individual participant maps were averaged within studies before being shared. Details of each study, the associated receptor/transporter, tracer, number of healthy participants, age and reference with full methodological details can be found in Table 1. A more extensive table can be found in the supplementary material (Supplementary Table 3), which additionally includes the PET camera, number of males and females, PET modeling method, reference region, scan length, modeling notes and additional references, if applicable. In all cases, only healthy participants were scanned ( $n = 1,238$ ; 718 males and 520 females). Images were acquired using best practice imaging protocols recommended for each radioligand<sup>56</sup>. Altogether, the images are an estimate proportional to receptor densities, and we, therefore, refer to the measured value (that is, binding potential and tracer distribution volume) simply as density. Note that the NMDA receptor tracer ( $[^{18}\text{F}]\text{GE-179}$ ) binds to open (that is, active) NMDA receptors<sup>86,95</sup>. PET images were all registered to the MNI-ICBM 152 non-linear 2009 (version c, asymmetric) template and then parcellated to 100, 200 and 400 regions according to the Schaefer atlas<sup>12</sup>. Receptors and transporters with more than one mean image of the same tracer (that is, 5-HT<sub>1B</sub>, D<sub>2</sub>, mGluR<sub>5</sub> and VACHT) were combined using a weighted average after confirming that the images are highly correlated to one another (Supplementary Fig. 13a). Finally, each tracer map corresponding to each receptor/transporter was z-scored across regions and concatenated into a final region by receptor matrix of relative densities.

In some cases, more than one tracer map was available for the same neurotransmitter receptor/transporter. We show the comparisons between tracers in Supplementary Fig. 13b for the following neurotransmitter receptors/transporters: 5-HT<sub>1A</sub><sup>9,69</sup>, 5-HT<sub>1B</sub><sup>9,69,70</sup>, 5-HT<sub>2A</sub><sup>9,69,96</sup>, 5-HTT<sup>9,69</sup>, CB<sub>1</sub> (refs. (<sup>89,97</sup>)), D<sub>2</sub> (refs. (<sup>59,60,98,99</sup>)), DAT<sup>64,100</sup>, GABA<sub>A</sub><sup>8,64</sup>, MOR<sup>93,101</sup> and NET<sup>65,102</sup>. Here, we make some specific notes: (1) 5-HTT and GABA<sub>A</sub> involve comparisons between the same tracers (DASB and flumazenil, respectively), but one map is converted to density using autoradiography data (see ref. <sup>9</sup> and ref. <sup>8</sup>) and the other is not<sup>7,64,69</sup>; (2) raclopride is a popular D<sub>2</sub> tracer but has unreliable binding in the cortex and is, therefore, an inappropriate tracer to use for mapping D<sub>2</sub> densities in the cortex, but we show its comparison to FLB457 and another D<sub>2</sub> tracer, fallypride, for completeness<sup>98,99,103</sup>; and (3) the chosen carfentanil (MOR) map was collated across carfentanil images in the PET Turku Centre database—because our alternative map is a partly overlapping subset of participants, we did not combine the tracers into a single mean map<sup>93,101</sup>.

Synapse density in the cortex was measured in 76 healthy adults (45 males,  $48.9 \pm 18.4$  years of age) by administering [ $^{11}\text{C}$ ]UCB-J, a PET tracer that binds to the synaptic vesicle glycoprotein 2A (SV2A)<sup>104</sup>. Data were collected on an HRRT PET camera for 90 minutes after injection. Non-displaceable binding potential (BP<sub>ND</sub>) was modeled using SRTM2, with the centrum semiovale as reference and  $k'$  fixed to 0.027 (population value). This group-averaged map was first presented in ref. <sup>105</sup>.

### Autoradiography receptor data acquisition

Receptor autoradiography data were originally acquired as described in ref. <sup>6</sup>. Fifteen neurotransmitter receptor densities across 44 cytoarchitecturally defined areas were collected in three postmortem brains (age range: 72–77 years, two males). See Supplementary Table 1 for a complete list of receptors included in the autoradiography dataset; see Supplementary Table 2 in ref. <sup>6</sup> for the originally reported

receptor densities; and see [https://github.com/AlGoulas/receptor\\_principles](https://github.com/AlGoulas/receptor_principles) for machine-readable Python numpy files of receptor densities<sup>37</sup>. To best compare PET data analyses with the autoradiography dataset, a region-to-region mapping was manually created between the 44 available cortical areas in the autoradiography dataset and the 50 left hemisphere cortical Schaefer-100 regions. Four regions in the Schaefer atlas did not have a suitable mapping to the autoradiography atlas. As such, the 44-region autoradiography atlas was converted to 46 Schaefer left hemisphere regions. Finally, receptor densities were concatenated and z-scored to create a single map of receptor densities across the cortex.

### Structural and functional data acquisition

Following the procedure described in ref. <sup>106</sup>, we obtained structural and functional MRI data for 326 unrelated participants (age range: 22–35 years, 145 males) from the HCP (S900 release<sup>29</sup>). All four resting-state functional MRI scans (two scans (R/L and L/R phase-encoding directions) on day 1 and two scans (R/L and L/R phase-encoding directions) on day 2, each about 15 minutes long; TR = 720 ms), as well as diffusion-weighted imaging (DWI) data were available for all participants. All the structural and functional MRI data were pre-processed using HCP minimal pre-processing pipelines<sup>29,107</sup>. We provide a brief description of data pre-processing below, whereas detailed information regarding data acquisition and pre-processing is available elsewhere<sup>29,107</sup>.

### Structural network reconstruction

DWI data were pre-processed using the MRtrix3 package<sup>108</sup> (<https://www.mrtrix.org/>). More specifically, fiber orientation distributions were generated using the multi-shell, multi-tissue constrained spherical deconvolution algorithm from MRtrix<sup>109,110</sup>. White matter edges were then reconstructed using probabilistic streamline tractography based on the generated fiber orientation distributions<sup>111</sup>. The tract weights were then optimized by estimating an appropriate cross-section multiplier for each streamline following the procedure proposed by ref. <sup>112</sup>, and a connectivity matrix was built for each participant using the 100-region Schaefer parcellation<sup>12</sup>. A group consensus binary network was constructed using a method that preserves the density and edge-length distributions of the individual connectomes<sup>113</sup>. Edges in the group consensus network were assigned weights by averaging the log-transformed streamline count of non-zero edges across participants. Edge weights were then scaled to values between 0 and 1.

### Functional network reconstruction

All 3T functional MRI time series were corrected for gradient non-linearity, head motion using a rigid body transformation and geometric distortions using scan pairs with opposite phase encoding directions (R/L and L/R)<sup>106</sup>. Further pre-processing steps include co-registration of the corrected images to the T1w structural MR images, brain extraction, normalization of whole brain intensity, high-pass filtering (>2,000s full width at half maximum (FWHM); to correct for scanner drifts) and removing additional noise using the ICA-FIX process<sup>106,114</sup>. The pre-processed time-series were then parcellated to 100 cortical brain regions according to the Schaefer atlas<sup>12</sup>. The parcellated time series were used to construct functional connectivity matrices as a Pearson correlation coefficient between pairs of regional time series for each of the four scans of each participant. A group-average functional connectivity matrix was constructed as the mean functional connectivity across all individuals and scans.

### Structure–function coupling

Structure–function coupling at every brain region is defined as the adjusted  $R^2$  of a simple linear regression model that fits regional communicability (that is, the communicability between a brain region to every other brain region) to regional functional connectivity (that is,



the functional connectivity between a brain region and every other brain region). Communicability is defined as the weighted average of all walks and paths between two brain regions and represents diffusive communication<sup>26,115</sup>. Additionally, communicability has been previously demonstrated as an important bridge between brain structure and function<sup>27</sup>. In the receptor-informed model, receptor similarity between the region of interest and every other region was included as an additional independent variable. The significance of the receptor-informed structure–function coupling was assessed against a null distribution of adjusted  $R^2$  from a model that adds a rotated regional receptor similarity vector (10,000 repetitions). This ensures that the increase in  $R^2$  when receptor information is included in the model is robust against the addition of a random variable with identical spatial autocorrelation.

### MEG power

Six-minute resting-state eyes-open magnetoencephalography (MEG) time series were acquired from the HCP (S1200 release) for 33 unrelated participants (age range: 22–35 years, 17 males)<sup>29,107</sup>. Complete MEG acquisition protocols can be found in the HCP S1200 Release Manual. For each participant, we computed the power spectrum at the vertex level across six different frequency bands: delta (2–4 Hz), theta (5–7 Hz), alpha (8–12 Hz), beta (15–29 Hz), low gamma (30–59 Hz) and high gamma (60–90 Hz), using the open-source software Brainstorm<sup>116</sup>. The pre-processing was performed by applying notch filters at 60, 120, 180, 240 and 300 Hz and was followed by a high-pass filter at 0.3 Hz to remove slow-wave and DC-offset artifacts. Pre-processed sensor-level data were used to obtain a source estimation on HCP's fsLR4k cortex surface for each participant. Head models were computed using overlapping spheres, and the data and noise covariance matrices were estimated from the resting-state MEG and noise recordings. Brainstorm's linearly constrained minimum variance (LCMV) beamformers method was applied to obtain the source activity for each participant. Welch's method was then applied to estimate power spectrum density (PSD) for the source-level data, using overlapping windows of length 4 seconds with 50% overlap. Average power at each frequency band was then calculated for each vertex (that is, source). Source-level power data were then parcellated into 100 cortical regions for each frequency band<sup>12</sup>.

### ENIGMA cortical abnormality maps

The ENIGMA (Enhancing Neuroimaging Genetics through Meta-Analysis) consortium is a data-sharing initiative that relies on standardized image acquisition and processing pipelines, such that disorder maps are comparable<sup>117</sup>. Patterns of cortical abnormality were collected for 13 neurological, neurodevelopmental and psychiatric disorders from the ENIGMA consortium and the Enigma toolbox (<https://github.com/MICA-MNI/ENIGMA>; ref. <sup>118</sup>), including: 22q11.2 deletion syndrome (22q)<sup>119</sup>, ADHD<sup>120</sup>, ASD<sup>121</sup>, idiopathic generalized epilepsy<sup>122</sup>, right temporal lobe epilepsy<sup>122</sup>, left temporal lobe epilepsy<sup>122</sup>, depression<sup>123</sup>, OCD<sup>124</sup>, schizophrenia<sup>125</sup>, BD<sup>126</sup>, obesity<sup>127</sup>, schizotypy<sup>128</sup> and PD<sup>129</sup>. Although most disorders show decreases in cortical thickness, some (for example, 22q, ASD and schizotypy) also show regional increases in cortical thickness. We, therefore, refer to the disorder profiles as 'cortical abnormalities'. All cortical abnormality maps were collected from adult patients (except for ASD for which only an age-aggregated (2–64 years) map was available), following identical processing protocols, for a total of over 21,000 scanned patients against almost 26,000 controls. The values for each map are z-scored effect sizes (Cohen's  $d$ ) of cortical thickness in patient populations versus healthy controls. Note that the native and only representation of ENIGMA datasets is the Desikan–Killiany atlas (68 cortical regions)<sup>130</sup>. For visualization purposes, data are inverted such that larger values represent greater cortical thinning. Imaging and processing protocols can be found at <http://enigma.ini.usc.edu/protocols/>.

### Dominance analysis

Dominance analysis seeks to determine the relative contribution ('dominance' of each independent variable to the overall fit (adjusted  $R^2$ )) of the multiple linear regression model (<https://github.com/dominance-analysis/dominance-analysis> (ref. <sup>31</sup>)). This is done by fitting the same regression model on every combination of input variables ( $2^p - 1$  submodels for a model with  $p$  input variables). Total dominance is defined as the average of the relative increase in  $R^2$  when adding a single input variable of interest to a submodel, across all  $2^p - 1$  submodels. The sum of the dominance of all input variables is equal to the total adjusted  $R^2$  of the complete model, making total dominance an intuitive method that partitions the total effect size across predictors. Therefore, unlike other methods of assessing predictor importance, such as methods based on regression coefficients or univariate correlations, dominance analysis accounts for predictor–predictor interactions and is interpretable. Dominance was then normalized by the total fit ( $R^2_{\text{adj}}$ ) of the model, to make dominance fully comparable both within and across models.

### Cognitive meta-analytic activation

Probabilistic measures of the association between voxels and cognitive processes were obtained from Neurosynth, a meta-analytic tool that synthesizes results from more than 15,000 published functional MRI studies by searching for high-frequency keywords (such as 'pain' and 'attention') that are published alongside functional MRI voxel coordinates (<https://github.com/neurosynth/neurosynth>, using the volumetric association test maps<sup>34</sup>). This measure of association is the probability that a given cognitive process is reported in the study if there is activation observed at a given voxel. Although more than 1,000 cognitive processes are reported in Neurosynth, we focused primarily on cognitive function and, therefore, limit the terms of interest to cognitive and behavioral terms. These terms were selected from the Cognitive Atlas, a public ontology of cognitive science<sup>131</sup>, which includes a comprehensive list of neurocognitive processes. We used 123 terms, ranging from umbrella terms ('attention' and 'emotion') to specific cognitive processes ('visual attention' and 'episodic memory'), behaviors ('eating' and 'sleep') and emotional states ('fear' and 'anxiety'). The coordinates reported by Neurosynth were parcellated according to the Schaefer-100 atlas and z-scored<sup>12</sup>. The probabilistic measure reported by Neurosynth can be interpreted as a quantitative representation of how regional fluctuations in activity are related to psychological processes. The full list of cognitive processes is shown in Supplementary Table 2.

### Partial least squares analysis

Partial least squares (PLS) analysis was used to relate neurotransmitter receptor distributions to functional activation. PLS is an unsupervised multivariate statistical technique that decomposes the two datasets into orthogonal sets of latent variables with maximum covariance<sup>132</sup>. The latent variables consist of receptor weights, cognitive weights and a singular value that represents the covariance between receptor distributions and functional activations that is explained by the latent variable. Receptor and cognitive scores are computed by projecting the original data onto the respective weights, such that each brain region is assigned a receptor and cognitive score. Finally, receptor loadings are computed as the Pearson's correlation between receptor densities and receptor scores and vice versa for cognitive loadings. Note that PLS analysis does not (1) speak to causal relationships between receptors and cognition, (2) make specific univariate receptor–cognition associations and (3) preclude the existence of additional relationships between receptors and cognitive function.

The significance of the latent variable was assessed on the singular value, against the spin-test (see the 'Null models' section). In the present report, only the first latent variable was significant; the remaining latent variables were not analyzed further.

Finally, the correlation between receptor and cognitive scores was cross-validated (see the ‘Distance-dependent cross-validation’ section). The empirical correlation between receptor and cognitive scores across all brain regions was  $r(98) = 0.70$ ; the mean training set correlation was  $r(98) = 0.71$ ; and the mean test set correlation was  $r(98) = 0.54$  and  $P_{\text{spin}} = 0.046$ , one-sided.

### Distance-dependent cross-validation

The robustness of each multilinear model was assessed by cross-validating the model by using a distance-dependent method<sup>28</sup>. Specifically, this method was applied to every multilinear regression model (Figs. 3c, 4 and 6) and the PLS model (Fig. 5). For each brain region (source node), we selected the 75% closest regions as the training set and the remaining 25% of brain regions as the test set, for a total of 100 repetitions in the Schaefer atlas and 68 repetitions in the Desikan–Killiany atlas. This stratification procedure minimizes the dependence among the two sets due to spatial autocorrelation. In the case of multilinear regression models, the model was fit on the training set, and the predicted test set output variable (regional functional connectivity, MEG power or disorder maps) was correlated to the empirical test set values. The distribution of Pearson’s correlations between predicted and empirical variables across all repetitions (that is, all brain regions) can be found in Supplementary Fig. 2 (structure–function coupling), Supplementary Fig. 3 (MEG power) and Supplementary Fig. 7 (disorder maps).

In the case of the PLS analysis, the model was fit on the training set, and the weights were projected onto the test set to calculate predicted receptor and cognitive scores. Training and test sets were defined as described above, and the procedure was repeated for each brain region as the source node (100 repetitions). The correlation between receptor and cognitive score was separately calculated in the training and test set. The significance of the mean out-of-sample correlation was assessed against a permuted null model, constructed by repeating the cross-validation on spatial autocorrelation-preserving permutations of the functional association matrix (1,000 repetitions; Fig. 5d).

### Null models

Spatial autocorrelation-preserving permutation tests were used to assess statistical significance of associations across brain regions, termed ‘spin tests’<sup>24,25,133</sup>. We created a surface-based representation of the parcellation on the FreeSurfer fsaverage surface via files from the Connectome Mapper toolkit (<https://github.com/LTSS/cmp>). We used the spherical projection of the fsaverage surface to define spatial coordinates for each parcel by selecting the coordinates of the vertex closest to the center of the mass of each parcel. These parcel coordinates were then randomly rotated, and original parcels were reassigned the value of the closest rotated parcel (10,000 repetitions). Parcels for which the medial wall was closest were assigned the value of the next most proximal parcel instead. The procedure was performed at the parcel resolution rather than the vertex resolution to avoid upsampling the data and to each hemisphere separately. Note that the spin test was not applied to autoradiography data because of missing samples. A permutation test was applied instead.

A second null model was used to test whether receptor similarity is greater in connected regions than unconnected regions. This model generates a null structural connectome that preserves the density, edge length and degree distributions of the empirical structural connectome<sup>22,133</sup>. In brief, edges were binned according to Euclidean distance. Within each bin, pairs of edges were selected at random and swapped. This procedure was then repeated 10,000 times. To compute a  $P$  value, the mean receptor similarity of unconnected edges was subtracted from the mean receptor similarity of connected edges, and this difference was compared to a null distribution of differences computed on the rewired networks.

### Reporting Summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

### Data availability

All data used to perform the analyses can be found at [https://github.com/netneurolab/hansen\\_receptors](https://github.com/netneurolab/hansen_receptors). Volumetric PET images, including receptor images and synaptic density, are included in neuromaps (<https://github.com/netneurolab/neuromaps>) where they can be converted between template spaces<sup>94</sup>. Autoradiography data are available in Supplementary Table 2 of ref. <sup>6</sup>. The HCP dataset, including diffusion-weighted MRI, functional MRI and MEG, is available at <https://db.humanconnectome.org/>. Neurosynth data are available at <https://neurosynth.org/>. The ENIGMA datasets are available through the ENIGMA consortium and the ENIGMA Toolbox (<https://github.com/MICA-MNI/ENIGMA> (ref. <sup>134</sup>)). Parcellation atlases, including the Schaefer-100 and Desikan–Killiany atlas, were obtained from netneurottools (<https://github.com/netneurolab/netneurottools>).

### Code availability

All code used to perform the analyses can be found at [https://github.com/netneurolab/hansen\\_receptors](https://github.com/netneurolab/hansen_receptors).

### References

- Markello, R. D. et al. neuromaps: structural and functional interpretation of brain maps. *Nat. Methods* (2022). <https://www.nature.com/articles/s41592-022-01625-w>
- Schoenberger, M. et al. In vivo [<sup>18</sup>F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges in rodents and nonhuman primates. *ACS Chem. Neurosci.* **9**, 298–305 (2018).
- Talbot, P. S. et al. Extended characterisation of the serotonin 2A (5-HT<sub>2A</sub>) receptor-selective PET radiotracer <sup>11</sup>C-MDL100907 in humans: quantitative analysis, test–retest reproducibility, and vulnerability to endogenous 5-HT tone. *Neuroimage* **59**, 271–285 (2012).
- Laurikainen, H. et al. Sex difference in brain CB1 receptor availability in man. *Neuroimage* **184**, 834–842 (2019).
- Jaworska, N. et al. Extra-striatal D<sub>2/3</sub> receptor availability in youth at risk for addiction. *Neuropsychopharmacology* **45**, 1498–1505 (2020).
- Alakurtti, K. et al. Long-term test–retest reliability of striatal and extrastriatal dopamine D<sub>2/3</sub> receptor binding: study with [<sup>11</sup>C] raclopride and high-resolution PET. *J. Cereb. Blood Flow Metab.* **35**, 1199–1205 (2015).
- Sasaki, T. et al. Quantification of dopamine transporter in human brain using pet with <sup>18</sup>F-FE-PE2I. *J. Nucl. Med.* **53**, 1065–1073 (2012).
- Turtonen, O. et al. Adult attachment system links with brain mu opioid receptor availability in vivo. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* **6**, 360–369 (2021).
- Hesse, S. et al. Central noradrenaline transporter availability in highly obese, non-depressed individuals. *Eur. J. Nucl. Med. Mol. Imaging* **44**, 1056–1064 (2017).
- Dagher, A. & Palomero-Gallagher, N. Mapping dopamine with positron emission tomography: a note of caution. *Neuroimage* **207**, 116203 (2020).
- Finnema, S. J. et al. Kinetic evaluation and test–retest reproducibility of [<sup>11</sup>C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. *J. Cereb. Blood Flow Metab.* **38**, 2041–2052 (2018).
- Hansen, J. Y. et al. Local molecular and global connectomic contributions to cross-disorder cortical abnormalities. *Nat. Commun.* **13**, 4682 (2022).

106. de Wael, R. V. et al. Anatomical and microstructural determinants of hippocampal subfield functional connectome embedding. *Proc. Natl Acad. Sci. USA* **115**, 10154–10159 (2018).
107. Glasser, M. F. et al. The minimal preprocessing pipelines for the Human Connectome Project. *Neuroimage* **80**, 105–124 (2013).
108. Tournier, J.-D. et al. MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation. *Neuroimage* **202**, 116137 (2019).
109. Dhollander, T., Raffelt, D. & Connelly, A. Unsupervised 3-tissue response function estimation from single-shell or multi-shell diffusion MR data without a co-registered T1 image. ISMRM Workshop on Breaking the Barriers of Diffusion MRI. [https://www.researchgate.net/publication/307863133\\_Unsupervised\\_3-tissue\\_response\\_function\\_estimation\\_from\\_single-shell\\_or\\_multi-shell\\_diffusion\\_MR\\_data\\_without\\_a\\_co-registered\\_T1\\_image](https://www.researchgate.net/publication/307863133_Unsupervised_3-tissue_response_function_estimation_from_single-shell_or_multi-shell_diffusion_MR_data_without_a_co-registered_T1_image) (ISMRM, 2016).
110. Jeurissen, B., Tournier, J.-D., Dhollander, T., Connelly, A. & Sijbers, J. Multi-tissue constrained spherical deconvolution for improved analysis of multi-shell diffusion MRI data. *Neuroimage* **103**, 411–426 (2014).
111. Tournier, J. D., Calamante, F. & Connelly, A. Improved probabilistic streamlines tractography by 2nd order integration over fibre orientation distributions. *Proc. Int. Soc. Magn. Res. Med.* [https://cds.ismrm.org/protected/10MProceedings/PDFfiles/1670\\_4298.pdf](https://cds.ismrm.org/protected/10MProceedings/PDFfiles/1670_4298.pdf) (2010).
112. Smith, R. E., Tournier, J.-D., Calamante, F. & Connelly, A. SIFT2: enabling dense quantitative assessment of brain white matter connectivity using streamlines tractography. *Neuroimage* **119**, 338–351 (2015).
113. Betzel, R. F., Griffa, A., Hagmann, P. & Mišić, B. Distance-dependent consensus thresholds for generating group-representative structural brain networks. *Netw. Neurosci.* **3**, 475–496 (2019).
114. Salimi-Khorshidi, G. et al. Automatic denoising of functional MRI data: combining independent component analysis and hierarchical fusion of classifiers. *Neuroimage* **90**, 449–468 (2014).
115. Estrada, E. & Hatano, N. Communicability in complex networks. *Phys. Rev. E Stat. Nonlin. Soft Matter Phys.* **77**, 036111 (2008).
116. Tadel, F., Baillet, S., Mosher, J. C., Pantazis, D. & Leahy, R. M. Brainstorm: a user-friendly application for MEG/EEG analysis. *Comput. Intell. Neurosci.* **2011**, 879716 (2011).
117. Thompson, P. M. et al. ENIGMA and global neuroscience: a decade of large-scale studies of the brain in health and disease across more than 40 countries. *Transl. Psychiatry* **10**, 100 (2020).
118. Larivière, S. et al. The ENIGMA Toolbox: cross-disorder integration and multiscale neural contextualization of multisite neuroimaging datasets. *Nat. Methods* **18**, 698–700 (2021). <https://www.nature.com/articles/s41592-021-01186-4>
119. Sun, D. et al. Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: convergence with idiopathic psychosis and effects of deletion size. *Mol. Psychiatry* **25**, 1822–1834 (2020).
120. Hoogman, M. et al. Brain imaging of the cortex in ADHD: a coordinated analysis of large-scale clinical and population-based samples. *Am. J. Psychiatry* **176**, 531–542 (2019).
121. Van Rooij, D. et al. Cortical and subcortical brain morphometry differences between patients with autism spectrum disorder and healthy individuals across the lifespan: results from the ENIGMA ASD working group. *Am. J. Psychiatry* **175**, 359–369 (2018).
122. Whelan, C. D. et al. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. *Brain* **141**, 391–408 (2018).
123. Schmaal, L. et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA major depressive disorder working group. *Mol. Psychiatry* **22**, 900–909 (2017).
124. Boedhoe, P. S. et al. Cortical abnormalities associated with pediatric and adult obsessive-compulsive disorder: findings from the ENIGMA obsessive-compulsive disorder working group. *Am. J. Psychiatry* **175**, 453–462 (2018).
125. Van Erp, T. G. et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. *Biol. Psychiatry* **84**, 644–654 (2018).
126. Hibar, D. et al. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA bipolar disorder working group. *Mol. Psychiatry* **23**, 932–942 (2018).
127. Opel, N. et al. Brain structural abnormalities in obesity: relation to age, genetic risk, and common psychiatric disorders. *Mol. Psychiatry* **26**, 4839–4852 (2021).
128. Kirschner, M. et al. Cortical and subcortical neuroanatomical signatures of schizotypy in 3,004 individuals assessed in a worldwide ENIGMA study. *Mol. Psychiatry* **27**, 1167–1176 (2021).
129. Laansma, M. A. et al. International multicenter analysis of brain structure across clinical stages of Parkinson's disease. *Mov. Disord.* **36**, 2583–2594 (2021).
130. Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage* **31**, 968–980 (2006).
131. Poldrack, R. A. et al. The cognitive atlas: toward a knowledge foundation for cognitive neuroscience. *Front. Neuroinform.* **5**, 17 (2011).
132. Krishnan, A., Williams, L. J., McIntosh, A. R. & Abdi, H. Partial least squares (PLS) methods for neuroimaging: a tutorial and review. *Neuroimage* **56**, 455–475 (2011).
133. Vasa, F. & Misic, B. Null models in network neuroscience. *Nat. Rev. Neurosci.* **23**, 493–504 (2022).
134. Larivière, S. et al. The ENIGMA Toolbox: multiscale neural contextualization of multisite neuroimaging datasets. *Nat. Methods* **18**, 698–700 (2021).

## Acknowledgements

We thank V. Bazinet, Z.-Q. Liu, F. Milisav, L. Suarez, B. Vazquez-Rodriguez, M. Li and A. Luppi for their comments and suggestions on the manuscript. This research was undertaken thanks, in part, to funding from the Canada First Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives initiative. B.M. acknowledges support from the Natural Sciences and Engineering Research Council of Canada (NSERC Discovery Grant RGPIN no. 017-04265) and from the Canada Research Chairs Program. J.Y.H. acknowledges support from the Helmholtz International BigBrain Analytics & Learning Laboratory, the Natural Sciences and Engineering Research Council of Canada and the Fonds de recherches de Québec. M.N. acknowledges support from the Independent Research Fund Denmark (DFF-0129-00004B). E.K. acknowledges support from the Savoy Foundation for Epilepsy, the American Epilepsy Society Early Career Physician Scientist Award and the Canadian Institutes of Health Research (CIHR) MOP-93614. J.P.C. was supported by a *British Journal of Anaesthesia*/Royal College of Anaesthetists grant from the National Institute of Academic Anaesthesia. Some of the PET receptor data included in this manuscript were supported by Novo Nordisk Foundation grant OpenNeuroPET (0063277). Some of the PET receptor data included in this manuscript were supported by a Medical Research Council (MRC) PET Neuroscience programme grant (Training and Novel Probes Programme in PET Neurochemistry (MR/K02308X/1)) and from an MRC Developmental Pathway Funding Scheme grant (MR/L013215/1). PET receptor data collected in Cambridge were supported by the National Institute for Health and Care Research Cambridge Biomedical Research Centre (BRC-1215-20014). The funders had no



role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

## Author contributions

J.Y.H. and B.M. conceived the study and wrote the manuscript, with valuable revision from all authors. J.Y.H. performed the formal analysis, with contributions from G.S. and R.D.M. J.Y.H. interpreted the results, with contributions from G.S., R.D.M., N.P.-G., J.M.S., L.T., A.D. and B.M. K.S., S.M.L.C., M.N., V.B., Y.W., J.-D.G., E.A., S.S., S.G.S., J.M.D., G.B., T.F., T.W.S., R.N.S., M.G., M.J.K., J.S.D., J.P.C., T.D.F., F.I.A., C.J.M., A.H., J.-P.S., S.G., J.H., M.-A.B., M.L., E.K., P.R.-N., M.G., G.M.K., R.E.G. and L.T. provided data. B.M. was the project administrator.

## Competing interests

J.M.D. is currently an employee of, and has financial interest in, Biogen, Inc. However, the work contributing to this manuscript is in no way related to his employment at Biogen. R.D.M. is currently employed by Octave Bioscience. However, the work

contributing to this manuscript is in no way related to his employment at Octave Bioscience. The remaining authors declare no competing interests.

## Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41593-022-01186-3>.

**Correspondence and requests for materials** should be addressed to Bratislav Mistic.

**Peer review information** *Nature Neuroscience* thanks Amy Kuceyeski, Trevor Robbins and Theodore Satterthwaite for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- |                                     |                                     |  |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A description of all covariates tested   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

**Data collection** enigmatoolbox v1.1.1 (<https://github.com/MICA-MNI/ENIGMA>) was used for fetching ENIGMA data. MEG data was processed using the open software toolbox Brainstorm v220420. HCP structural data was processed using MRtrix3 v3.0.0

**Data analysis** All code used to analyze data can be found at [https://github.com/netneurolab/hansen\\_receptors](https://github.com/netneurolab/hansen_receptors). Data was analyzed using Python 3.8.10, MATLAB R2022a, netneurolab v0.2.3 and neuromaps v0.0.3.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All data used to perform the analyses can be found at [https://github.com/netneurolab/hansen\\_receptors](https://github.com/netneurolab/hansen_receptors). Volumetric PET images, including receptor images and synaptic density, are included in neuromaps (<https://github.com/netneurolab/neuromaps>) where they can be easily converted between template spaces. Autoradiography data is available in Supplementary Table 2 of Zilles & Palomero-Gallagher 2017, Frontiers in Neuroanatomy. The HCP dataset, including diffusion weighted MRI, fMRI, and MEG is available at <https://db.humanconnectome.org/>. Neurosynth data is available at <https://neurosynth.org/>. The ENIGMA datasets are

available through the ENIGMA consortium and the ENIGMA toolbox (<https://github.com/MICA-MNI/ENIGMA>). Parcellation atlases including the Schaefer-100 and Desikan-Killiany atlas were fetched from netneurotools (<https://github.com/netneurolab/netneurotools>).

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample size calculations were performed. We collated as many PET tracer images as possible to construct a comprehensive (19-receptor/transporter) atlas. HCP data was used because of the large number of subjects and the relatively equal male/female balance. For HCP data, only unrelated subjects were included. For PET data, only healthy subjects were included. The ENIGMA dataset was selected because of the large number of subjects in each meta-analysis and because it contains many brain maps for diseases/disorders/conditions that have been similarly processed such that comparison between datasets is possible.
Data exclusions	No data was excluded.
Replication	The analysis pipeline was conducted and replicated: (1) at the Schaefer-100 parcellation resolution, (2) at the Schaefer-200 parcellation resolution, (3) at the Schaefer-400 parcellation resolution, (4) using the 68-node Desikan Killiany atlas alongside structural/functional connectomes from the Lausanne atlas. Furthermore, we recalculated the receptor similarity matrix in a leave-one-out fashion, and confirmed that no single receptor/transporter exerts undue influence on this similarity matrix (correlation between leave-one-out similarity matrix and original similarity matrix >0.98 for all receptors). Finally, analyses were repeated using autoradiography data for 15 receptors as opposed to PET data for 19 receptors/transporters.
Randomization	No randomization was performed as this study does not include experimental groups.
Blinding	Blinding is not relevant to this study because it does not include experimental groups.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input type="checkbox"/>	<input checked="" type="checkbox"/> MRI-based neuroimaging

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	Demographic information for all PET subjects can be found in Table 1.
Recruitment	Only data from healthy control subjects were used in the analyses.
Ethics oversight	Each individual PET study was approved, details can be found in the references found in Table 1.

Note that full information on the approval of the study protocol must also be provided in the manuscript.



# Magnetic resonance imaging

## Experimental design

Design type	Resting-state fMRI and diffusion-weighted MRI
Design specifications	Following the procedure described in Vos De Wael et al., 2018, we obtained structural and functional magnetic resonance imaging (MRI) data for 326 unrelated participants (age range 22–35 years, 145 males) from the Human Connectome Project (HCP; S900 release). All four resting state fMRI scans (two scans (R/L and L/R phase encoding directions) on day 1 and two scans (R/L and L/R phase encoding directions) on day 2, each about 15 min long; TR=720 ms), as well as diffusion weighted imaging (DWI) data were available for all participants. All the structural and functional MRI data were pre-processed using HCP minimal pre-processing pipelines. Detailed information regarding data acquisition and pre-processing is available elsewhere (Van Essen et al., 2013, Glasser et al., 2013)
Behavioral performance measures	No behavioural measures were recorded during the fMRI runs.

## Acquisition

Imaging type(s)	Functional and diffusion-weighted MRI
Field strength	3T
Sequence & imaging parameters	Multi-band sequence; functional images have a 2-mm isotropic signal resolution, structural modalities were acquired on a Siemens Skyra 3T scanner and included a T1-weighted MPRAGE sequence at an isotropic resolution of 0.7mm, and a T2-weighted SPACE at an isotropic resolution of 0.7mm. More details on imaging protocols and procedures are available at <a href="http://protocols.humanconnectome.org/HCP/3T/imaging-protocols.html">http://protocols.humanconnectome.org/HCP/3T/imaging-protocols.html</a> .
Area of acquisition	Whole-brain
Diffusion MRI	<input type="checkbox"/> Used <input type="checkbox"/> Not used

## Preprocessing

Preprocessing software	We used the HCP data that was previously preprocessed. This preprocessing was done using FSL 5.0.6, FreeSurfer 5.3.0-HCP, and Connectome Workbench v1.1.1.
Normalization	Image processing includes correcting for gradient distortion caused by non-linearities, correcting for bias field distortions, and registering the images to a standard reference space.
Normalization template	fs_LR_32k surface mesh
Noise and artifact removal	FMRIB's ICA-based X-noiseier (FIX) and global signal regression
Volume censoring	No volume censoring was performed.

## Statistical modeling & inference

Model type and settings	Functional and structural connectomes were used for comparison with PET-derived receptor similarity.
Effect(s) tested	We tested whether receptor similarity is greater when regions are connected (SC) or within the same intrinsic functional network (fMRI).
Specify type of analysis:	<input checked="" type="checkbox"/> Whole brain <input type="checkbox"/> ROI-based <input type="checkbox"/> Both
Statistic type for inference (See <a href="#">Eklund et al. 2016</a> )	NA
Correction	NA

## Models & analysis

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Functional and/or effective connectivity
<input type="checkbox"/>	<input checked="" type="checkbox"/> Graph analysis
<input type="checkbox"/>	<input checked="" type="checkbox"/> Multivariate modeling or predictive analysis
Functional and/or effective connectivity	We used functional connectivity, which was constructed by correlated pairwise regional functional time series, and averaging this across subjects.
Graph analysis	We used structural connectivity (weighted) matrices. Structural connectivity between pairs of regions was

Graph analysis

measured in terms of fiber density, defined as the number of streamlines between two regions, normalized by the average length of the streamlines and average surface area of the two regions. The goal of this normalization is to compensate for the bias toward longer fibers inherent in the tractography procedure, as well as differences in region size.

Multivariate modeling and predictive analysis

Regional vectors of functional and connectivity were used in a multilinear regression model which fit measures of structure (distance, path length, communicability) and receptor similarity to functional connectivity.